{
  "experiment_id": "15a0a5bcdef518ad0109cf4cdf1d2400",
  "task_name": "narrowing_of_broad_synonyms",
  "task_hash": "9dc5c284f909400a12e111d9ec8ba4e5",
  "model_id": "openrouter/auto",
  "system_instructions": "You are a metadata curation assistant. Your task is to help improve and correct metadata \naccording to the specific instructions provided for each task. Be precise, accurate, and \nfollow the guidelines carefully.\n",
  "temperature": 0.0,
  "thinking": false,
  "tools": [],
  "timestamp": "2025-11-19T20:33:43.471416",
  "task_result": {
    "task_name": "narrowing_of_broad_synonyms",
    "num_samples": 10,
    "results": [
      {
        "sample_index": 0,
        "input": {
          "diagnosis": "Neurofibromatosis",
          "assay": "DNA sequencing",
          "tumorType": "Neurofibroma"
        },
        "response": {
          "success": true,
          "content": "{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"targeted sequencing\",\n  \"tumorType\": \"Neurofibroma\"\n}",
          "model_id": "openrouter/auto",
          "usage": {
            "inputTokens": 2404,
            "outputTokens": 1454,
            "totalTokens": 3858
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584050-tndqvXU3mFsuidUhcRqN",
            "provider": "OpenAI",
            "model": "openai/gpt-5",
            "object": "chat.completion",
            "created": 1763584052,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "completed",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"targeted sequencing\",\n  \"tumorType\": \"Neurofibroma\"\n}",
                  "refusal": null,
                  "reasoning": "**Evaluating genomic sequencing options**\n\nI'm thinking about which genomic DNA approach to recommend without more context. It seems like \"whole genome sequencing,\" \"whole exome sequencing,\" or \"targeted sequencing\" could be options, with \"targeted sequencing\" or \"whole exome sequencing\" possibly being more typical for NF1 and neurofibromas.\n\nBut I want to make sure to pick the narrowest appropriate method. If there's no specific context, maybe I lean toward \"whole exome sequencing\" as a common choice while being cautious not to guess.**Choosing sequencing options**\n\nI need to pick a specific option from an enum related to DNA sequencing. The choices could include \"whole genome sequencing,\" \"whole exome sequencing,\" or \"targeted sequencing,\" with \"targeted sequencing\" being the narrowest general choice. It seems safer because it doesn\u2019t imply whole genome coverage. While \"DNA sequencing\" could refer to \"Sanger sequencing,\" which is older, \"targeted sequencing\" is common for NF1 mutation analysis. \n\nConsidering the task to narrow synonyms, \"targeted sequencing\" seems like a good pick, especially for the tumor type \"Neurofibroma,\" which matches an enum value.**Deciding on neurofibroma specifics**\n\nThey\u2019re asking for a narrow choice regarding neurofibroma types, like \"Localized Neurofibroma\" or \"Cutaneous Neurofibroma.\" However, without more context, it's tricky to specify one. The term \"Neurofibroma\" is valid on its own, so perhaps it shouldn\u2019t be narrowed down too much, since it fits the schema well.\n\nRegarding the sequencing type, I consider that \"whole exome sequencing\" might actually be more specific compared to \"targeted sequencing.\" It seems like a good option to go with for this task based on that reasoning.**Choosing the right sequencing method**\n\nWES is specific, but I'm unsure if it's the correct choice for this context. The instruction suggests using what's appropriate, and for NF1, \"targeted sequencing\" or \"Sanger sequencing\" of the large NF1 gene is common. However, Sanger sequencing can be cumbersome, so targeted next-gen panels or whole exome sequencing are often preferred.\n\nConsidering the task\u2019s pattern, they seem to want me to map \"DNA sequencing\" to a more specific category, like \"targeted sequencing\" or \"whole genome sequencing.\" I think \"targeted sequencing\" fits well, though it's a bit general. But I wonder if \"whole genome sequencing\" is expected when unspecified. I wish I was more certain!**Finalizing JSON output**\n\nI'm considering the ontology for \"DNA sequencing\" to narrow down to \"targeted sequencing,\" which is a safe choice. While \"whole genome sequencing\" and \"whole exome sequencing\" are broader, \"targeted sequencing\" fits well because it\u2019s still a general term but more specific than the whole category. \n\nThe instruction emphasizes using exact controlled terminology, and \"targeted sequencing\" is present in the enum, so that\u2019s what I\u2019ll go with. \n\nHere's the final JSON:\n\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"targeted sequencing\",\n  \"tumorType\": \"Neurofibroma\"\n}",
                  "reasoning_details": [
                    {
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.summary",
                      "summary": "**Evaluating genomic sequencing options**\n\nI'm thinking about which genomic DNA approach to recommend without more context. It seems like \"whole genome sequencing,\" \"whole exome sequencing,\" or \"targeted sequencing\" could be options, with \"targeted sequencing\" or \"whole exome sequencing\" possibly being more typical for NF1 and neurofibromas.\n\nBut I want to make sure to pick the narrowest appropriate method. If there's no specific context, maybe I lean toward \"whole exome sequencing\" as a common choice while being cautious not to guess.**Choosing sequencing options**\n\nI need to pick a specific option from an enum related to DNA sequencing. The choices could include \"whole genome sequencing,\" \"whole exome sequencing,\" or \"targeted sequencing,\" with \"targeted sequencing\" being the narrowest general choice. It seems safer because it doesn\u2019t imply whole genome coverage. While \"DNA sequencing\" could refer to \"Sanger sequencing,\" which is older, \"targeted sequencing\" is common for NF1 mutation analysis. \n\nConsidering the task to narrow synonyms, \"targeted sequencing\" seems like a good pick, especially for the tumor type \"Neurofibroma,\" which matches an enum value.**Deciding on neurofibroma specifics**\n\nThey\u2019re asking for a narrow choice regarding neurofibroma types, like \"Localized Neurofibroma\" or \"Cutaneous Neurofibroma.\" However, without more context, it's tricky to specify one. The term \"Neurofibroma\" is valid on its own, so perhaps it shouldn\u2019t be narrowed down too much, since it fits the schema well.\n\nRegarding the sequencing type, I consider that \"whole exome sequencing\" might actually be more specific compared to \"targeted sequencing.\" It seems like a good option to go with for this task based on that reasoning.**Choosing the right sequencing method**\n\nWES is specific, but I'm unsure if it's the correct choice for this context. The instruction suggests using what's appropriate, and for NF1, \"targeted sequencing\" or \"Sanger sequencing\" of the large NF1 gene is common. However, Sanger sequencing can be cumbersome, so targeted next-gen panels or whole exome sequencing are often preferred.\n\nConsidering the task\u2019s pattern, they seem to want me to map \"DNA sequencing\" to a more specific category, like \"targeted sequencing\" or \"whole genome sequencing.\" I think \"targeted sequencing\" fits well, though it's a bit general. But I wonder if \"whole genome sequencing\" is expected when unspecified. I wish I was more certain!**Finalizing JSON output**\n\nI'm considering the ontology for \"DNA sequencing\" to narrow down to \"targeted sequencing,\" which is a safe choice. While \"whole genome sequencing\" and \"whole exome sequencing\" are broader, \"targeted sequencing\" fits well because it\u2019s still a general term but more specific than the whole category. \n\nThe instruction emphasizes using exact controlled terminology, and \"targeted sequencing\" is present in the enum, so that\u2019s what I\u2019ll go with. \n\nHere's the final JSON:\n\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"targeted sequencing\",\n  \"tumorType\": \"Neurofibroma\"\n}"
                    },
                    {
                      "id": "rs_07c7d743e3ac7ffd01691e2835fc9481958d903b81aa1fb6b8",
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2404,
              "completion_tokens": 1454,
              "total_tokens": 3858,
              "completion_tokens_details": {
                "reasoning_tokens": 1408
              }
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole exome sequencing",
          "tumorType": "Plexiform Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 2404,
          "output_tokens": 1454,
          "total_tokens": 3858
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 1,
        "input": {
          "diagnosis": "NF",
          "assay": "exome sequencing",
          "tumorType": "sarcoma"
        },
        "response": {
          "success": true,
          "content": "{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Sarcoma\"\n}",
          "model_id": "openrouter/auto",
          "usage": {
            "inputTokens": 2398,
            "outputTokens": 621,
            "totalTokens": 3019
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584082-4MkWh55ABhhpEk5MY7Ww",
            "provider": "OpenAI",
            "model": "openai/gpt-5",
            "object": "chat.completion",
            "created": 1763584084,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "completed",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Sarcoma\"\n}",
                  "refusal": null,
                  "reasoning": "**Narrowing synonyms for diagnosis**\n\nI need to focus on narrowing down the broad term \"NF\" to specific schema values like diagnosis, assay, and tumorType. \"NF\" is ambiguous and could refer to neurofibromatosis type 1 or 2. In the schema, \"Neurofibromatosis type 1\" is listed, and there's also \"NF2-related schwannomatosis.\" But since \"NF\" alone is not specific, I\u2019ll proceed with \"Neurofibromatosis type 1\" as the safer choice, especially since it might relate to sarcoma and MPNST in this context.**Refining tumor terminology**\n\nI\u2019m considering exome sequencing, which might help analyze tumor predisposition, but I need to be careful and avoid guesswork. The goal is to narrow down synonyms accurately. For \"NF,\" the appropriate term is likely \"Neurofibromatosis type 1,\" especially since the tumor type is \"sarcoma,\" which matches what\u2019s in the schema. I also need to ensure \"exome sequencing\" is corrected to \"whole exome sequencing\" in the target. Given that MPNST is associated with NF1, it makes sense to choose \"Neurofibromatosis type 1.\"**Returning corrected metadata**\n\nI need to return the corrected metadata in JSON format with the same structure, using three keys: diagnosis, assay, and tumorType. I'll set the diagnosis to \"Neurofibromatosis type 1,\" the assay to \"whole exome sequencing,\" and the tumorType to \"Sarcoma.\" \n\nI\u2019ll check to make sure that each new value is allowed and that they exist exactly. Since there are no additional corrections needed, I\u2019ll maintain the same structure as the input and produce the final JSON accordingly.",
                  "reasoning_details": [
                    {
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.summary",
                      "summary": "**Narrowing synonyms for diagnosis**\n\nI need to focus on narrowing down the broad term \"NF\" to specific schema values like diagnosis, assay, and tumorType. \"NF\" is ambiguous and could refer to neurofibromatosis type 1 or 2. In the schema, \"Neurofibromatosis type 1\" is listed, and there's also \"NF2-related schwannomatosis.\" But since \"NF\" alone is not specific, I\u2019ll proceed with \"Neurofibromatosis type 1\" as the safer choice, especially since it might relate to sarcoma and MPNST in this context.**Refining tumor terminology**\n\nI\u2019m considering exome sequencing, which might help analyze tumor predisposition, but I need to be careful and avoid guesswork. The goal is to narrow down synonyms accurately. For \"NF,\" the appropriate term is likely \"Neurofibromatosis type 1,\" especially since the tumor type is \"sarcoma,\" which matches what\u2019s in the schema. I also need to ensure \"exome sequencing\" is corrected to \"whole exome sequencing\" in the target. Given that MPNST is associated with NF1, it makes sense to choose \"Neurofibromatosis type 1.\"**Returning corrected metadata**\n\nI need to return the corrected metadata in JSON format with the same structure, using three keys: diagnosis, assay, and tumorType. I'll set the diagnosis to \"Neurofibromatosis type 1,\" the assay to \"whole exome sequencing,\" and the tumorType to \"Sarcoma.\" \n\nI\u2019ll check to make sure that each new value is allowed and that they exist exactly. Since there are no additional corrections needed, I\u2019ll maintain the same structure as the input and produce the final JSON accordingly."
                    },
                    {
                      "id": "rs_011c3e66318d254401691e2854a2d08196acdd606317f53157",
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "gAAAAABpHihkXK8l6km3ZymC4qXYkl8YFX6fsQUXsrRoKKtqDi0kht_fYhO4kTfYw5kFdVnGnU3CTD1UQ1QmpyZ_Ux1IZXhtMYWEO-Z2RmLOAxoaejcFJtJ9Fkpg6luID47Le9yeF4GsKANjPz-JjqzTS1VDexkr41PFy0ektk4TwCusIPCdDCS85jB7kfq6_RUyIalINaPNPZR5_7noYHIfRTYu2MwwcBLZPpEi8W1pftyv2v1UjBn9OqcAbD3oX1a2P0AhpjWMjod_fo-PlwgEjkzAjJk9IYAGy-XD-wasI_SDYKbO5HI2ePHMQ1CBKaZQmgLr0IYP6G8ZnaFTcGg1R5wxNPPc3hV2gv2hqw9z9TszndGQjcdVaUeScUDUC24ySFTAL9o_JAIe-dKJ8e5XbO5vecW2EwYgZ1pOLigxmNrJtwsndhSeqjyZv9QC_ay8p5bPcXY8ZabzacG14_J4Euo00XhAEIbYNT-USUY1UDPw0LQZAE0b-OAMoETEL7tE73Mg9mgwHq0_MjHtpi8vWUofUqBZHHhyWdoRd85wmJcXXHi_ZHis650z-VPhEZomvpdwGGhxpx1r6eX_Tl9eYJRqByAP_vLm4l9F3eeb_CzuOPIN6uQA0qmm7QsWqGBpaPt2JN7hRj2viU9QLKNe33S-3aEcDutGmQb3DONfkgYoWP15jIX0iYe21X7xHllFTjb_yyc06j_Q0WPIzmpP2_mD2edbowmKHk8VuJYPuyZRSRNiR_JF92T1fNxkeUV3FcqM_07-u1CL5CWErX2OmsVoovr1imKVkl8vgq1fhWweaWsOmaAE_7S3_KAMPgjO8V8qZpCrvbkrh8WYZ3RlFVmNegCs1xl8LLQ-Fi8NRk6gGovZ2W-R4mimTzIL2sc2tik_UODTcyWwyIK5EFg0h9eKuDi6vUHgh9XF0K2DHQMKk9AMX8H3gkgcrkadisDN7m2u_XRKF8-J8DuQ9paxNA_czpxisH8w_VySJ7lI1WTJYALfDH9fHjzTJFpJSI3POCR5F7PiM-tVI5vb-mOws-xS1hu60QAbHUQjXXCbBsgupiCCQxfe_FubFaFHrcm5rPwu1vgpmyXfPegRINLd9w7C-Ph7Wzqh3nBJQpUv_fEQRMSIu7gwOk9kD_jFFMfE8iHuQU66Zna58nFODpjNOzOCa3DOrgEeN2XtPbZ0fHpBatWU1g5Y5kxndiyl2Bjayu--qk9CAqMQi5adHMiJDCNYLC3Qw2K0so-jiZXBdwSuyw9PQ43m9EfCDCm9rkV59YVX2_6XTmJjAr9y8NE45-M4QqGXsXg4IZ9CyPpT7_kQtkD6qvS-eb1z5l_fJJPHbofpbDP8qKJQDTiSeRvfbkP1beYMACuKAlJHG502mqB3PO6l6Gf-5dYJDk4cMfLEDXuwU1urPR_15HN4OL6MY2pJzXH_HRk4mLS1ft6TBkjbdtqCAZg5PNv9qRU_hYOlu_ZIkm1mq64sre0WM-VqnDXPHj5vC0ByvVvyZ3HKMpvPkbGgpJtbuRxKJKm35RCOPGx7q36c3unXI8JvQA2xaBYBBLAATONZu-BTK1Z2NOQb4J5aN4JfjwN0exTRpiPKal7moKt4phbMKddy8o1wezuDS7kGrVtkrUmMp_dWKGly4jVFPxKR3hxZ3nGLZzMLY2fBsnkj_zaBP8lqHo9_DPCpL9w0NyAOQyIn785nUjsDaOTnumbnpojH_os3gDS51CZNDnFGoU4X2Yy_8VeNXj5OZGFNFc9MJh-iQUoP3AjKE9EZM29akQUFNd2v7ClwXdZa3U7RxW6NCv5D2tAoDBE0EAx0Fu_BHB4cx2GbP8SThzZRUi1ZuYCFI2uMQEpRJ1v8H76ddul3SUo2AAUtjuZBrEwkT5IbV2Wji5AzMZHVDulbotyb2GHO2dN2RNDjpwI1WorN_T3-a_dXVmqvywKeWUGZOzK4QTScEUZp6TxhMes7ka7fxDE9w8hhZbDZJjhKrugMUCQHWjyG1YQihjA5i1Y9eZJ9BFhU1BkbG6CT0QuHrSp233OBm9iER6wZb7YUkJ4hzHUqsG4ZrPTeHoHISIiNyGhYdwiToHGVypcsmOw5PKt3fnh-MhlCHzumAGxLgSXI8XiqPVQpVFdHFpGZ-LS33i4-l587-3WuE80z4wd2z_7sLwnkCi1L7OO2SdF0L1Rhe5N7muSiRCtXa5o18jiJggYuv1z1KukdVvjvRrX9teJ0LHR_xjvHuxLrGn8C5kSnd8hB0G2x7EYBNFEsNhoIJ5cR_diWMb9iHM3Lpejq7rOYdUOrHVXw45GTY-dbaVQvWOLM37McYoGsKgvK89WQVj7aYMqf2T8gqnqdSL4JPF1AXpqQzvFAL0W-yYxHJmNGXg9RbuOlDq6kFVS9i3mEXbggKY8kz-p3ulHSb27DeCtJAhPjJdEW5b-bvzSWl-4yDHcOXj8xt8FQJt2d0dIHR9HnxHk0LVV5EQqMY4Eq6d2SVJyXLMKu9mtzveM1nqc2rR4P5sltCrm2BqCFMK-o5k4PqfyOp4SGUGFIWCKIXl4F9tQLk5pL2jc6EDjM8Go-yJqZlGD5T2-FfkOzshk8-8LociQCONxddQI_pCjYxyBEcj7m0vF6qThh5ZHs8b9HdOum5OVoPKGLHQoKX_R6FhuMdT3q9WsA9yz8FdWGnMquMT6x_D79GrzeVm_3Js-CUpSmNcvufoGh3AXce6P83FjBobSyfWQTHPi85RAlbBTVy0jWHWvGQltDxghyZUVset_1f3yJkrmcd5zaaPKqBnuCBxa0RTx2spJCu6lQGrlV-5xAxcz73Or1nvi90TDpbE7e8VdcRGNqampZsNvnrlBk4-LLbyIKeJm4BTQ6_3Xi_95hUHeV8KLrPmpGERdnONjUr7JGcphsDR7I2OqVWozpGeqdynX9pu7v4HzBmhb2u24JsU4o8B9izj72NhCAv2LB5K2CUus2eBC5QxzZyheQ7tUswkdZ5mj8IayCil_oH_ji7MWqFmue-S7quijH2rpil73XlkXHyriWa5NI9_NQRlHrZ-7bIM81MFX7SWFYzxFXYf_vWDXoZm-3jT-AaxL1fg2S1ywP2ELHXuCkq9yxx_2G2vCxl4DyNn4okPhfyh2ky9I7UjD8I8TLr6hj7GsDJzdiJypX7eCo4XlcdKQPvr542Gf3bX1NaADtYoG489CSAk0zRxLqF5wsfZf5Vv6QBlAGWVbFTvJ9aQL5ifdx2_lUl0RImLYFYyTPvHlmqqkmAItqQweiWcXP9lGnY0FJPucEBOsHbocrlyFllMRSZK4-xSDIW4-YBt2TJEC7UcdBTuUtxKURZdjSk7rUccgU9b67KnDXVb30oBZR4OmXALQ0wxUE5pSpR30s54K9igLboBghHBz_pxsjCzRfhb_fcSX6LCEpBTVoF72aqb8YtUy8GIJDhmhB_CZGOecn08ZbJVLDBr_pWJak2vbkdToRSmKrFadLlRDOV1gYcogSCJ_ihpqhAVtdlu9oTEd4Ov8EuPoeixsNSxLVgvDJU5H7uwXaVbOWup4yZuwc_mXkf8G0GYjhED9B0rs4Pma3m6IE2pRvxScSNrLR_yhmqyZtaduk1MTi04hcq5dPZ1AMLJZWNv0SlbgXQqcJ21Dq1yPhgmbksLcxPNdUdLJ8FyLyMxTKzKa8RajxeUzgAzVYawHvP3c2fw_c2CrU3ctY0L14FDGHAAPjES0qbTLRasP-lL5o_4_ugJO8ucrUr6Xn2PzJryichdALYlnsYgRB8eqqWnmhVF9mRgkoF1HKGE1Y6pmrqV2H-gmyDfHpT1b6L8VfPeoWtqbKM3s8sOG4JzITY5zAnoo_XbBE_-7B0HJS2iLDRkwMv63ULD68Mguhuayzy6VBfEGTIPyLnmaktWm9b78NBZFSPfZ8m-XfYxgux09oHlFUGf7PVTM07CLNsn1HwbjGPzcyygkanFfkPw3qNH7vPiKtwrnckv5sJI0ycfdaYay0P6GeN7232xEJJP03ldShk7u-pQeDMScgZVeRFjpvouGHCSwVTvJZSt6osYHgAO8uztyGdXOOIsLuixF37ZFFu4kUmTc0QZEUsiou3qwGUA-C6usdhdoO"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2398,
              "completion_tokens": 621,
              "total_tokens": 3019,
              "completion_tokens_details": {
                "reasoning_tokens": 576
              }
            }
          }
        },
        "score": 0.6666666666666666,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole exome sequencing",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 2398,
          "output_tokens": 621,
          "total_tokens": 3019
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 2,
        "input": {
          "diagnosis": "Neurofibromatoses",
          "assay": "assay by high throughput sequencer",
          "tumorType": "Nerve Sheath Neoplasm"
        },
        "response": {
          "success": true,
          "content": "{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Neurofibroma\"\n}",
          "model_id": "openrouter/auto",
          "usage": {
            "inputTokens": 2411,
            "outputTokens": 1839,
            "totalTokens": 4250
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584101-Y4PAzSgvMR1mG9Zbgqkw",
            "provider": "OpenAI",
            "model": "openai/gpt-5",
            "object": "chat.completion",
            "created": 1763584102,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "completed",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Neurofibroma\"\n}",
                  "refusal": null,
                  "reasoning": "**Narrowing medical terms**\n\nI need to narrow down broad synonyms for specific terms. The input mentions \"Neurofibromatoses,\" which can include \"Neurofibromatosis type 1,\" \"NF2-related schwannomatosis,\" and \"Schwannomatosis.\" Without context, it\u2019s tricky to choose. Maybe \"Schwannomatosis-NOS\" or \"Unknown\" could work as fallback options. However, \"Neurofibromatosis type 1\" is likely the most commonly used term. There\u2019s also \"tumorType\": \"Nerve Sheath Neoplasm,\" which can refer to various specific options like \"Schwannoma\" or \"Neurofibroma,\" all under that umbrella term.**Narrowing down tumor types**\n\nWithout specific details, I\u2019m considering terms like \"NF1-Associated Tumor,\" \"NF2-Associated Tumor,\" or just \"tumor.\" But \"tumor\" feels too broad, and \"Unknown\" isn't helpful either. Nerve sheath neoplasms are likely \"Schwannoma,\" \"Neurofibroma,\" or MPNST, and based on the diagnosis of \"Neurofibromatoses,\" we know NF1 links to neurofibromas while NF2 connects to schwannomas. For the assay type, \"assay by high throughput sequencer\" probably narrows down best to \"targeted sequencing\" among the options available.**Choosing sequencing terms**\n\nI can't just guess here. The schema indicates \"next generation targeted sequencing,\" so I'm considering broad phrases like \"assay by high throughput sequencer.\" This term is often used, but it's ambiguous. I notice they want me to narrow down to controlled terminology. Usually, \"assay by high throughput sequencer\" maps to \"whole genome sequencing\" unless otherwise specified. However, I could also think about \"targeted sequencing.\" Without specific context, \"whole genome sequencing\" might be a safer choice, though it's not definitive. Maybe \"whole transcriptome sequencing\" is an option too, but that isn't clearly indicated.**Choosing appropriate terms**\n\nI\u2019m considering using \"next generation targeted sequencing,\" which is a bit generic but falls under the NGS category. The term \"targeted\" suggests a panel, which complicates things. Leaving it as \"Unknown\" might not work because there's no \"Unknown\" term in the assay list. I suppose we could default to \"whole genome sequencing\" as a standard mapping. For \"Nerve Sheath Neoplasm,\" choosing \"Schwannoma\" is common for NF2/schwannomatosis, while \"Neurofibroma\" works for NF1. Given the diagnosis of \"Neurofibromatoses,\" I think narrowing down to \"Neurofibromatosis type 1\" makes sense, linking it to \"Neurofibroma\" as a typical nerve sheath tumor. Just need to be cautious about assumptions!**Finalizing metadata choices**\n\nThe task is to narrow broad synonyms in the provided metadata, likely using broad synonyms initially. I'll choose specific recognized terms, like \"Neurofibromatosis type 1,\" which is the most typical for NF1. For assays, \"whole exome sequencing\" is often used for tumor profiling, so I\u2019ll lean towards that. While \"whole genome sequencing\" is broader, it might not be as specific as I need. After careful consideration, I'll finalize the mapping as follows: \n\n- Diagnosis: \"Neurofibromatosis type 1\"\n- Assay: \"whole exome sequencing\"\n- Tumor type: \"Neurofibroma\" \n\nThis feels cohesive and appropriate based on the context, so I\u2019m ready to return the JSON structure now!",
                  "reasoning_details": [
                    {
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.summary",
                      "summary": "**Narrowing medical terms**\n\nI need to narrow down broad synonyms for specific terms. The input mentions \"Neurofibromatoses,\" which can include \"Neurofibromatosis type 1,\" \"NF2-related schwannomatosis,\" and \"Schwannomatosis.\" Without context, it\u2019s tricky to choose. Maybe \"Schwannomatosis-NOS\" or \"Unknown\" could work as fallback options. However, \"Neurofibromatosis type 1\" is likely the most commonly used term. There\u2019s also \"tumorType\": \"Nerve Sheath Neoplasm,\" which can refer to various specific options like \"Schwannoma\" or \"Neurofibroma,\" all under that umbrella term.**Narrowing down tumor types**\n\nWithout specific details, I\u2019m considering terms like \"NF1-Associated Tumor,\" \"NF2-Associated Tumor,\" or just \"tumor.\" But \"tumor\" feels too broad, and \"Unknown\" isn't helpful either. Nerve sheath neoplasms are likely \"Schwannoma,\" \"Neurofibroma,\" or MPNST, and based on the diagnosis of \"Neurofibromatoses,\" we know NF1 links to neurofibromas while NF2 connects to schwannomas. For the assay type, \"assay by high throughput sequencer\" probably narrows down best to \"targeted sequencing\" among the options available.**Choosing sequencing terms**\n\nI can't just guess here. The schema indicates \"next generation targeted sequencing,\" so I'm considering broad phrases like \"assay by high throughput sequencer.\" This term is often used, but it's ambiguous. I notice they want me to narrow down to controlled terminology. Usually, \"assay by high throughput sequencer\" maps to \"whole genome sequencing\" unless otherwise specified. However, I could also think about \"targeted sequencing.\" Without specific context, \"whole genome sequencing\" might be a safer choice, though it's not definitive. Maybe \"whole transcriptome sequencing\" is an option too, but that isn't clearly indicated.**Choosing appropriate terms**\n\nI\u2019m considering using \"next generation targeted sequencing,\" which is a bit generic but falls under the NGS category. The term \"targeted\" suggests a panel, which complicates things. Leaving it as \"Unknown\" might not work because there's no \"Unknown\" term in the assay list. I suppose we could default to \"whole genome sequencing\" as a standard mapping. For \"Nerve Sheath Neoplasm,\" choosing \"Schwannoma\" is common for NF2/schwannomatosis, while \"Neurofibroma\" works for NF1. Given the diagnosis of \"Neurofibromatoses,\" I think narrowing down to \"Neurofibromatosis type 1\" makes sense, linking it to \"Neurofibroma\" as a typical nerve sheath tumor. Just need to be cautious about assumptions!**Finalizing metadata choices**\n\nThe task is to narrow broad synonyms in the provided metadata, likely using broad synonyms initially. I'll choose specific recognized terms, like \"Neurofibromatosis type 1,\" which is the most typical for NF1. For assays, \"whole exome sequencing\" is often used for tumor profiling, so I\u2019ll lean towards that. While \"whole genome sequencing\" is broader, it might not be as specific as I need. After careful consideration, I'll finalize the mapping as follows: \n\n- Diagnosis: \"Neurofibromatosis type 1\"\n- Assay: \"whole exome sequencing\"\n- Tumor type: \"Neurofibroma\" \n\nThis feels cohesive and appropriate based on the context, so I\u2019m ready to return the JSON structure now!"
                    },
                    {
                      "id": "rs_00f81a22f61a4edd01691e28673df88193a801bdfcaafe7ecc",
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2411,
              "completion_tokens": 1839,
              "total_tokens": 4250,
              "completion_tokens_details": {
                "reasoning_tokens": 1792
              }
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole genome sequencing",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 2411,
          "output_tokens": 1839,
          "total_tokens": 4250
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 3,
        "input": {
          "diagnosis": "neurocutaneous syndrome",
          "assay": "spectroscopy",
          "tumorType": "unknown"
        },
        "response": {
          "success": true,
          "content": "{\n  \"diagnosis\": \"Unknown\",\n  \"assay\": \"FTIR spectroscopy\",\n  \"tumorType\": \"Unknown\"\n}",
          "model_id": "openrouter/auto",
          "usage": {
            "inputTokens": 2399,
            "outputTokens": 1315,
            "totalTokens": 3714
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584138-Oh879KsglG5WPKhc0JAI",
            "provider": "OpenAI",
            "model": "openai/gpt-5",
            "object": "chat.completion",
            "created": 1763584139,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "completed",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "{\n  \"diagnosis\": \"Unknown\",\n  \"assay\": \"FTIR spectroscopy\",\n  \"tumorType\": \"Unknown\"\n}",
                  "refusal": null,
                  "reasoning": "**Narrowing synonyms in metadata**\n\nThe system's instruction mentions narrowing broad synonyms, suggesting I should find a more specific term that relates closely to the synonyms used. For example, \"neurocutaneous syndrome\" could refer to \"Neurofibromatosis type 1\" but might not be exact. In the context of NF/schwannomatosis, it could relate to NF1 or NF2. If I'm unsure, I could mark it as \"Unknown.\" The same applies to \"spectroscopy,\" where \"FTIR spectroscopy\" seems like a specific term, but I shouldn't guess if I\u2019m uncertain.**Evaluating spectroscopy terms**\n\nI'm trying to determine whether to assign \"Unknown\" for the diagnosis because I can't assume anything about tumors or cells. For the assay, I might choose \"mass spectrometry,\" as it's a specific technique under the broader umbrella of spectroscopy and is listed. However, the user mentioned \"spectroscopy,\" not specifically \"mass spectrometry.\" \"FTIR spectroscopy\" could be a closer match. In biomedical contexts, spectroscopy often means NMR or MRI spectroscopy, and \"magnetic resonance spectroscopy\" is specifically listed. Without more details, both FTIR and MRS are possibilities, but MRS is more frequent for brain tumor imaging. I need to avoid making too many assumptions here.**Narrowing synonyms for assays**\n\nThe user wants me to narrow broad synonyms rather than assign \"Unknown\" unless absolutely necessary. For the assay, I could choose something from the list like \"mass spectrometry\" or other specific techniques. If \"spectroscopy\" is mentioned, it might imply \"mass spectrometry,\" which is part of spectrometric methods but not strictly the same. I think linking \"spectroscopy\" to \"FTIR spectroscopy\" as a narrower term might be acceptable, though it\u2019s not necessarily correct. If there's ambiguity, I could lean toward \"Unknown,\" but there's no \"Unknown\" option for the assay, so I'll need to select something that matches the enumeration available.**Finalizing JSON structure**\n\nI\u2019ve decided to choose \"FTIR spectroscopy\" since it\u2019s the generic name for the assay. For diagnosis and tumorType, I'll set both to \"Unknown.\" However, I noticed that while there's a distinction between \"Schwannomatosis-NOS\" and \"Schwannomatosis,\" the term \"neurocutaneous syndrome\" isn\u2019t allowed. That means I need to correct it to a controlled term, opting for \"Unknown\" when necessary. I\u2019ll double-check the casing to ensure it's exact. Finally, I\u2019ll return the structured JSON as specified:\n\n{\n  \"diagnosis\": \"Unknown\",\n  \"assay\": \"FTIR spectroscopy\",\n  \"tumorType\": \"Unknown\"\n}",
                  "reasoning_details": [
                    {
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.summary",
                      "summary": "**Narrowing synonyms in metadata**\n\nThe system's instruction mentions narrowing broad synonyms, suggesting I should find a more specific term that relates closely to the synonyms used. For example, \"neurocutaneous syndrome\" could refer to \"Neurofibromatosis type 1\" but might not be exact. In the context of NF/schwannomatosis, it could relate to NF1 or NF2. If I'm unsure, I could mark it as \"Unknown.\" The same applies to \"spectroscopy,\" where \"FTIR spectroscopy\" seems like a specific term, but I shouldn't guess if I\u2019m uncertain.**Evaluating spectroscopy terms**\n\nI'm trying to determine whether to assign \"Unknown\" for the diagnosis because I can't assume anything about tumors or cells. For the assay, I might choose \"mass spectrometry,\" as it's a specific technique under the broader umbrella of spectroscopy and is listed. However, the user mentioned \"spectroscopy,\" not specifically \"mass spectrometry.\" \"FTIR spectroscopy\" could be a closer match. In biomedical contexts, spectroscopy often means NMR or MRI spectroscopy, and \"magnetic resonance spectroscopy\" is specifically listed. Without more details, both FTIR and MRS are possibilities, but MRS is more frequent for brain tumor imaging. I need to avoid making too many assumptions here.**Narrowing synonyms for assays**\n\nThe user wants me to narrow broad synonyms rather than assign \"Unknown\" unless absolutely necessary. For the assay, I could choose something from the list like \"mass spectrometry\" or other specific techniques. If \"spectroscopy\" is mentioned, it might imply \"mass spectrometry,\" which is part of spectrometric methods but not strictly the same. I think linking \"spectroscopy\" to \"FTIR spectroscopy\" as a narrower term might be acceptable, though it\u2019s not necessarily correct. If there's ambiguity, I could lean toward \"Unknown,\" but there's no \"Unknown\" option for the assay, so I'll need to select something that matches the enumeration available.**Finalizing JSON structure**\n\nI\u2019ve decided to choose \"FTIR spectroscopy\" since it\u2019s the generic name for the assay. For diagnosis and tumorType, I'll set both to \"Unknown.\" However, I noticed that while there's a distinction between \"Schwannomatosis-NOS\" and \"Schwannomatosis,\" the term \"neurocutaneous syndrome\" isn\u2019t allowed. That means I need to correct it to a controlled term, opting for \"Unknown\" when necessary. I\u2019ll double-check the casing to ensure it's exact. Finally, I\u2019ll return the structured JSON as specified:\n\n{\n  \"diagnosis\": \"Unknown\",\n  \"assay\": \"FTIR spectroscopy\",\n  \"tumorType\": \"Unknown\"\n}"
                    },
                    {
                      "id": "rs_0d7d4abf7e01d69c01691e288c386c8197a9387439e3a72780",
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2399,
              "completion_tokens": 1315,
              "total_tokens": 3714,
              "completion_tokens_details": {
                "reasoning_tokens": 1280
              }
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "conventional MRI",
          "tumorType": "Unknown"
        },
        "token_usage": {
          "input_tokens": 2399,
          "output_tokens": 1315,
          "total_tokens": 3714
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 4,
        "input": {
          "diagnosis": "Not Applicable",
          "assay": "immunoassay",
          "tumorType": "neurofibroma"
        },
        "response": {
          "success": true,
          "content": "{\n  \"diagnosis\": \"Not Applicable\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}",
          "model_id": "openrouter/auto",
          "usage": {
            "inputTokens": 2403,
            "outputTokens": 681,
            "totalTokens": 3084
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584164-jDfCFDJYXfMP8ygLh95K",
            "provider": "OpenAI",
            "model": "openai/gpt-5",
            "object": "chat.completion",
            "created": 1763584165,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "completed",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "{\n  \"diagnosis\": \"Not Applicable\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}",
                  "refusal": null,
                  "reasoning": "**Clarifying precise terminology**\n\nI'm considering the instruction about using precise terminology. Since the context isn't clear, I think tumorType being Neurofibroma doesn't directly imply a specific diagnosis like Neurofibromatosis type 1. It might fit sporadic neurofibroma, which is common. Therefore, I feel it's best to keep \"Not Applicable\" for diagnosis. I'll format the corrected metadata as JSON, confirming the term \"immunoassay\" is correctly spelled in lower-case. Let\u2019s finalize it as follows:\n\n{\n  \"diagnosis\": \"Not Applicable\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}",
                  "reasoning_details": [
                    {
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.summary",
                      "summary": "**Clarifying precise terminology**\n\nI'm considering the instruction about using precise terminology. Since the context isn't clear, I think tumorType being Neurofibroma doesn't directly imply a specific diagnosis like Neurofibromatosis type 1. It might fit sporadic neurofibroma, which is common. Therefore, I feel it's best to keep \"Not Applicable\" for diagnosis. I'll format the corrected metadata as JSON, confirming the term \"immunoassay\" is correctly spelled in lower-case. Let\u2019s finalize it as follows:\n\n{\n  \"diagnosis\": \"Not Applicable\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}"
                    },
                    {
                      "id": "rs_03072ba9d150e23801691e28a622808195ab181c0ee9c81237",
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "gAAAAABpHiiyA2VQFPrAu-BnZW_ldDx85NUfHa8gOf6L-bkFGLTRE2Ho6NnM8PlBh5ovfxwyOV7GuaZyVG1yN45fjEINrKFfFDueXC6S2RuCwsu7Z-X9k8blLaGWoU_cPS8HCWrNExlP6yfwK3bVpMe2wgafIGHBGfwHSHwM3i7Rutps0TMFnFBjr5xMouWPssasI3cdyZlQayKeoJEXhSclMOn9AE9DymxGfmbzdGDG75f3wb2oO4MC04ajEmdVe2A4jbvKcM0hexXs-VgmbcKvhE7nrrKn-E4KRh4qZdshj8XwUcOWbTAeadW3SyMmXyIwxPU9dDsgW7woq_rqC6ifUzZEJep14maPKlDRCs8SU83rv6sQvbJIZriRGJkQ-eXskIZNrzjL5L0HWEufKu81Xz7jHYGRjJKUgoPJHTahgtCToO_86FbIByp15-u5PIQqyRMXRc79GUPnr7rilyid69ReGaHKxmjrmyKC3qxuk01AGU8egIoCaQMY7C8GT9FfdubbIqzjvUWyRXoeGzr9bruRWjVrHFu66PZ4N-rI3q39TT9ihuK89ulypiTEhtwWCeFyKwrZur9AyVYY6Y_lDwrp-4CCmduqa722rWoiTkWiv8rmYxvKLA9kg1TCcvyqIK8jKZV4vOyMQ2SSgJ9rz8VXhym2ufLqRRDoVryi1UF1SwH35g31gfkqnpOmqipknUhAO1RWWPHaDFmW6KlXXl2cxT-KiPhBOasYThD6UdmB-DtIG1OeUy-5b2wa1FbxIgpsYgfNGBCW-iGdOApbSHj4u0vxmNUydcWjroJ1WQ5XKPLzhCRXNEcWvZb6OROYqbq_JYRVDGW-zwa9_fWMEvTv-AZsRsQaxru4AYj007qWVZfm_vB2VPih_3YlLfuswfxXhpkTg8dU5hdx3S90JfUoIyUWnf3j858k4e-NIq3OtlTHWXZ2KCMXyAuxNHwkR8zs0UCMETv77WIRUYXTGgtkXf74wLktRhVr0oJueWVLrYjyAVVGHFaVuJh3tWt1GWVlZe1W2beJf_CNjGGYdJWZfjTJZGebM5SStEBvQ3mj7tRS4khOiYTwkeEJ0UqQsg0rZYgA-Hu4IE0uep0LcvKvkXnssfoRu48I4tImGWK72t7ptv1WzIoihl39Bd90beXlxPLpbSd8U45gvIUmz_EX8Q6hSZ_0jXckgCzakSN7xzNFzKVaE2SOBDJ5mCkVbf_7lK-PzsdY9ytFGKr066MlxuKU16mj4wLxnLz7kQwZ-gPmAqn6iPmU_lAo6FWiKOXS5pZfJpjwsCIKXW8exynlcE-amJNVTBBIZEe_F4STMpMGQj0bDkA3C8z4H7WE7R12XMX4VMvoIBz01X8rHmLp29pDn_KEv8tRAbXGLHXw4krFYIXyyzF1cnHpw-F5ApQQ--qjUoUh-UQHNcOWVGmfPm5KTIkQH3A-rhSD3WRUuU9xuV4uec4K-EqiqB_UKX_QsLeTNDDeuF_tFuZ510v5JSQCe_5b3QQUCdr0hvMTcH3QT7cT7vtEns0xYm1XDiLPPs3CU0kj_SvHZU_UwJ-J2yutB7V_7MF5BiHLRIhKQCKlZgtq5oR1L5g5t94H8rsWwlvkGAuUfHjHgnc4iZ-u23kg-tzad-vYG5JNZ-BhQnonLn_6m4ZfbOdqW54MNtU1vJeRup3HV0y4q1wfNJ_H3vY156mZGcDF7JXr98ANv3BsUxQYWA6EXHa8y5P8olWxBNmB8KzQ-89iw8-a-rAX8aW3mxhX0RN7LdYRjrH2qauEMhKdHhJpBhF2D4QNpq1QV2fLoWTJNF8gG0TMv2TGJwoeWOloHdNFV8prciD6GJpiKEG80VHlKDHCoEZp-B_UPovIBT1QsmbRBp_tDmUVw0gAVyGIeeI1HFd-nNCSxPUmAuRiuK0Yfj6gwKLvc0Q9i9sIcaB5DDYtTH04c8raspO3QF9favSa9xeqtnH4ZK_16wjX3KUjpuexqqJx7JZjuqQSO_ToUQxf_hTn3C9Sd838DWuuMCz3wedZjkW9dY0pHmWnI51p_smqoHeRJSogN7e_wiWXE5MqARTDkuCophaAtcKyNatqz8AqOmr6AxSS3wMywqkDmVbaVJ0FJKqdOvPaCOYF-xDKyX29Xfb2BQOuL9mCyCANbdqVQVxx16iiWbT5XX1ScDszZzkYTAP6_lrsXkt-SLXpQboLmEDGBx-Z8LNHWWTEHNyeEaLMZYXOgL9vyE-_ePOFaK5oL86eW82VrEswYpkkqgq9NMQKS8ZD-MYeYw9VuGnUbjs5UKl7vlnAK_7h3BDkx-PkkSIPGTCJhhqDEP4TIaHhHW57efoalCJiUsMbc4icMdXJ5Szx8EnC0rVsD4ausoUIx2aOEwvdA3bAp215act7W-_JE_t2kgxDDSYqoKB7K9mfIvfn3dYcKc7MF7Gm2hZ_l3-NK5DOynwrs1wlBL1bWj9DWTLWOdkuQVejU5cE8mUnLStig95D38UXALyw_tu7M56Wz5ZNmfvP5bNBRnIArUPRGFrpGu0eakkUPe-A_m-5RJMPhb7HI0ybGP7ZPVlW-wuP6XFI6woZlkCbDX3_c3_hFQCjMZ__eQtK2BmPC5x_mCwcbhDKqg00Y2zuUFv2IgZTeylwzbM0_Ly5fKt1XA2sRJXj5otE8accB86S_03cAVBiUwMm8_fNtVc2Gh581slxewSonkUGmjZ2dIP9WobTr41i9ydMkaihKr2oGY007fhB2ImRKaq1Qoro1k9wTIXmFapYSmLXjToS8ogQoH_c8nwdueJ6TsYcLv4FTNnWfndz_eP9YFEAfiJH3TK6cP3J5ejeRDMKLnaAlLZW2aWD8VV0pNlyA21qUgn_mnfNBuKWlh3n1StBKnfZNs_MYAS4cFr953sA1b1yewxECBA4Zhxsnwf2ekVnUgotMMI_pydlt708tHkUettBRRxrQ7A6HMKX8Dp7JDTpCeV7-Sgi4SnGHsJPwQwTuE61Q0r_WEx0d8BeSJ3B1MQyzIuzrts-cFHKL-NrHYC2q1_Oe9vKGD8DUgcaNjQH1tZTDPsvZlI9YDQ3czyixJWUMQDSEEA8vekCWcJVdywssR--_QPz43pjOFjgyYhy3AUtXQzTXXG8uymMOI_vVCSKyXJFv2dMScQ4supGH6GYeeLEZfvl4pPZM_4UkiQaPeTSonIPCA4zlIhdirTgCS12n8DrNbItkYQGigwrxEY-gbHOY3YZ1p7QD-kNgJwsq-yHjMN_CCxb6EcMFBSlWRW8g3t6PfDKk0ev5B3QZIaxhKuJ0GY4nvMkRaSpI2JC3zdbJWTCFSy0uek7Zh_3qLihpMymng5jmJWu6UG4KJPquQsyKICN2lhSnpM6qweHG5qaWyAtWFWVtEFP3FsVkr2RsAL1mjGjC5kbbudx9zSCb0TCSGDRfu3_9iMRPzgN0T9QUCA_1eL6dVhbfypwkLzyXaHGGgvonUFiFZfZRR9O_esrBTPISC3SJ8KW9hIsVdHwM4fjCk7lNTOVrjKX3YCeMXsVCTpOC35rFKlwAK-7u0NUiBZ8wOOT4DtNDHHxCIn00Cc8qGIDUkqUgIxzEXBj_ur4S-MU3bnpy_EYxlyGKWmFBgN_kAlWRzoUrgUhUWzrRRm9Z_N6_T8X-XOPn6n8mlWyyq5UlcOgIsBZSgjAWEL29Q4XI18XH6kd5twWgN9D21zOnfQOUuAq_st5AbZmScl0HzjWHppLlYxg8b_BKtH-6u_uVoyJdT3-r2fgzO3MPoYW3WLWNro5DSq6t_6IXg8FBB1FuUyrUjkKrCh9Nc2067r6Tc9aC61S1xFQLwKrOSBnrZ9hIkXi5xeglLADDgddQsHRb543iHfD3-3vj1ek5jXUyKZBqaYgZz3Th6OMhGGSCozELFL2Tt9xYEyQ9AQGdq3MfZfCaHX3cuvCzPdL1FAlBxJUMs9Br_k_ZklGCIuhcbMfggASQr2FBHhPgIfZc5bidFflEa8SF9U1TjE9ldHlNxBZOo4QYH4cfyZ_UykFR4FPKEOBYp_7PFc-3hUQMC0P1kzzhheUjVKHjngVqG1T5G8hEh1ZKnUEtqMv-BczlWLrg9r6B7wBizqKimlbY_XBLGJE_oLkHNSlj96DRBRHg5zLcDKcjdf6zZ-CtB2h2EzkGncfYUqar-YR3YRQIsB2YapdPhRAb7JDEVvJJC3p6YFWP4jRM3hsYX-VTnTuyX_isC0-Ks_iuZ97Yvi5SbYRKl3X3bxoICGcl46y2LDe_TqNiNJuixtT3FshZeV8k7Uh13Phx9cZ_L8U5h2urxeyzdJMhKf1kmk7rWDOjK-soWRHKeu556FUoOTAueaaihI2-ePq762m7MlSnW9JS-S1psXNnvL_XAA72bP8OrtQYVy5o4AoKp1optU_goj3WrqsjMgO8rOZt6BSdanWqto237KJQ9COAJqthY8OvrMNbvb37UI5b40LPwyJqYMeGx_7rFdqzmUHFE89rPZFxwmUgLGqSR5CgOvdhxQ0pc61C7ejZwWxSYQCPcZUaT4qA_4KYHmzIyQ5lZ5LmgGqY_ajfd6orhsi5vN_24HFX3n2eO1scEczr1ojVmb72xfe1uhlDf2Z3cc7nNLSPi9pLehk_OncRUr-vT9lsZZQPQN9LF7pN_SWF1Pt9eS5OrqbM8eqSOneDkUPeYxHqzpcCz4ysrWX"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2403,
              "completion_tokens": 681,
              "total_tokens": 3084,
              "completion_tokens_details": {
                "reasoning_tokens": 640
              }
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Not Applicable",
          "assay": "immunohistochemistry",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 2403,
          "output_tokens": 681,
          "total_tokens": 3084
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 5,
        "input": {
          "diagnosis": "neurofibromatosis",
          "assay": "plate based reporter assay",
          "tumorType": "benign neurofibroma"
        },
        "response": {
          "success": true,
          "content": "{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"FLIPR high-throughput cellular screening\",\n  \"tumorType\": \"Neurofibroma\"\n}",
          "model_id": "openrouter/auto",
          "usage": {
            "inputTokens": 2407,
            "outputTokens": 1715,
            "totalTokens": 4122
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584179-9JhHDOKspDyb3qZ9pWnr",
            "provider": "OpenAI",
            "model": "openai/gpt-5",
            "object": "chat.completion",
            "created": 1763584180,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "completed",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"FLIPR high-throughput cellular screening\",\n  \"tumorType\": \"Neurofibroma\"\n}",
                  "refusal": null,
                  "reasoning": "**Mapping user input to schema**\n\nI need to map user input to the correct schema enumerations by narrowing down broad synonyms into more specific terms. I should provide a JSON structure with keys for diagnosis, assay, and tumorType using exact controlled terms.\n\nFor the diagnosis of \"neurofibromatosis,\" I\u2019ll narrow it to \"Neurofibromatosis type 1,\" especially since neurofibromas are characteristic of NF1. Looking at tumorType, the broad term \"benign neurofibroma\" needs to be specified, and there are various neurofibroma types in the schema that need to be accounted for.**Determining assay details**\n\nFor the appropriate mapping, I think \"Neurofibroma\" fits well since no specific subtype is indicated. So for tumorType, I\u2019ll use \"Neurofibroma.\"\n\nNow, looking at the assay called \"plate-based reporter assay,\" it seems this could fall under several schema enumerations. There isn't a generic \"reporter assay,\" but I see options like \"massively parallel reporter assay\" and \"high-content screen.\" While the \"FLIPR high-throughput cellular screening\" is a specific instrument option, I might need to choose other specific assays such as the \"Luciferase reporter assay.\"**Narrowing assay terms**\n\nI see that there are several options like \"cell viability assay,\" \"BrdU proliferation assay,\" and \"EdU proliferation assay,\" but \"plate-based reporter assay\" feels a bit too vague. I should think about which schema term best fits this.\n\nI'm considering \"high content screen\" or \"FLIPR high-throughput cellular screening,\" both of which describe plate-based assays, but we need a more exact term. The closest might be \"massively parallel reporter assay\" (MPRA), but that's still not quite the same as a generic plate-based assay. If the input suggests a plate-based reporter assay, I'll go with \"massively parallel reporter assay\" only if the context supports that choice.**Selecting assay terms**\n\nI\u2019m realizing there\u2019s nothing confirming the right term. Options like \"cell viability assay\" or \"luminescent reporter\" aren\u2019t present, while \"FLIPR high-throughput cellular screening\" is a plate-based option and commonly used with reporter dyes. Generally, a \"reporter assay\" might involve luciferase, but I see there\u2019s no \"luciferase assay\" in the schema. \n\nI can consider \"high-content screen,\" which uses imaging-based plate assays, but that doesn't guarantee it's a reporter assay. If there's room for a more general assay mapping, I should focus on picking one exact existing value that fits best, like \"massively parallel reporter assay,\" but I\u2019m not super confident about that choice either.**Finalizing assay mapping**\n\nI need to narrow synonyms, but I\u2019m concerned about the risk of incorrect mapping. It seems there's no option for \"Unknown\" in the assay list to choose from, so I must select something else. \n\nThe only applicable choice appears to be \"massively parallel reporter assay,\" but it\u2019s tricky since it's typically associated with sequencing rather than a plate-based system. I should consider \"FLIPR high-throughput cellular screening\" instead, which is explicitly plate-based. \n\nAfter reviewing, I think my choices should be: \n- diagnosis: \"Neurofibromatosis type 1\"\n- assay: \"FLIPR high-throughput cellular screening\"\n- tumorType: \"Neurofibroma\"\n\nI\u2019ll return a JSON structure with these values, ensuring everything is spelled correctly and matches the enumerations.",
                  "reasoning_details": [
                    {
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.summary",
                      "summary": "**Mapping user input to schema**\n\nI need to map user input to the correct schema enumerations by narrowing down broad synonyms into more specific terms. I should provide a JSON structure with keys for diagnosis, assay, and tumorType using exact controlled terms.\n\nFor the diagnosis of \"neurofibromatosis,\" I\u2019ll narrow it to \"Neurofibromatosis type 1,\" especially since neurofibromas are characteristic of NF1. Looking at tumorType, the broad term \"benign neurofibroma\" needs to be specified, and there are various neurofibroma types in the schema that need to be accounted for.**Determining assay details**\n\nFor the appropriate mapping, I think \"Neurofibroma\" fits well since no specific subtype is indicated. So for tumorType, I\u2019ll use \"Neurofibroma.\"\n\nNow, looking at the assay called \"plate-based reporter assay,\" it seems this could fall under several schema enumerations. There isn't a generic \"reporter assay,\" but I see options like \"massively parallel reporter assay\" and \"high-content screen.\" While the \"FLIPR high-throughput cellular screening\" is a specific instrument option, I might need to choose other specific assays such as the \"Luciferase reporter assay.\"**Narrowing assay terms**\n\nI see that there are several options like \"cell viability assay,\" \"BrdU proliferation assay,\" and \"EdU proliferation assay,\" but \"plate-based reporter assay\" feels a bit too vague. I should think about which schema term best fits this.\n\nI'm considering \"high content screen\" or \"FLIPR high-throughput cellular screening,\" both of which describe plate-based assays, but we need a more exact term. The closest might be \"massively parallel reporter assay\" (MPRA), but that's still not quite the same as a generic plate-based assay. If the input suggests a plate-based reporter assay, I'll go with \"massively parallel reporter assay\" only if the context supports that choice.**Selecting assay terms**\n\nI\u2019m realizing there\u2019s nothing confirming the right term. Options like \"cell viability assay\" or \"luminescent reporter\" aren\u2019t present, while \"FLIPR high-throughput cellular screening\" is a plate-based option and commonly used with reporter dyes. Generally, a \"reporter assay\" might involve luciferase, but I see there\u2019s no \"luciferase assay\" in the schema. \n\nI can consider \"high-content screen,\" which uses imaging-based plate assays, but that doesn't guarantee it's a reporter assay. If there's room for a more general assay mapping, I should focus on picking one exact existing value that fits best, like \"massively parallel reporter assay,\" but I\u2019m not super confident about that choice either.**Finalizing assay mapping**\n\nI need to narrow synonyms, but I\u2019m concerned about the risk of incorrect mapping. It seems there's no option for \"Unknown\" in the assay list to choose from, so I must select something else. \n\nThe only applicable choice appears to be \"massively parallel reporter assay,\" but it\u2019s tricky since it's typically associated with sequencing rather than a plate-based system. I should consider \"FLIPR high-throughput cellular screening\" instead, which is explicitly plate-based. \n\nAfter reviewing, I think my choices should be: \n- diagnosis: \"Neurofibromatosis type 1\"\n- assay: \"FLIPR high-throughput cellular screening\"\n- tumorType: \"Neurofibroma\"\n\nI\u2019ll return a JSON structure with these values, ensuring everything is spelled correctly and matches the enumerations."
                    },
                    {
                      "id": "rs_0c118d6a93c86b6301691e28b509348190a5ca01cdc2837fa5",
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "gAAAAABpHikEtP_SdAATIicG8kzh1YuKSjN6p6IOf2h9ktI9-m7UCMwQzp6B-pb_lR_gazu289-sTPrB1oHI6Y8GqU391xTIiUrJYacFB0QuRYMOA0SqmEL5b_OH3gf50X3qkGuiw38rrXYvqbSagVcalCW3JPDSnC5hAN0uRcJJkExNAkdwIMQGe7CvuwKIw0570VOzGAf5v5zwneSG0aCexTEzCn95zjijswaT7kcJPTGnVO-sP2MtXZczX6q-Rv6SU_wcNl8u_6twe8SZtKMWOVRe0P3oP8TYxbAF95TgREUpxUi2X8zEpyGJXO7K0wjcXwYUNgoflYMWVORwP44HpYthGSiflXcofI9-jZimnQu93TYyeG0CnKUEp3dWKPsEDr0s70MIAsKToBNsCrMyzLO2Lsq1UiVfht-d6hihxgPz1fGpkPviDN4hgmajsK3aPwdJmUi8TG7js0bTRQfJBVU66nKrFo0m4nuaIwMnvUAWyWFmeN_20XaRJbFz0_1JFHdI127skPjDSBQYP1EyftbZC-5ofIFHqJg5jA-LdLfPgKtznL7Oskp5AnN3q4cN7xBIacUou5EurxUGaIIgnsQtwfnGrUcRpQNDMv6VeV3hAIIjmCgJN9pbMz8Q2A-Sib7IfkThdGsGW8szn0PJBTcjU5GlD6NMmkfYfPLIEQ9-gEaEpnD3H6LWtjj_abNUu4VLp_WZ9iLDQaWTNqloqIFJ7dhD_HDoqb5WZg_jm9j7IKM79nEhk1yl3qGaoh9-laStZSdByctGiLIfxvVb4nJxhWSLGo_8CE4kIeoqvwwLBqGWo08X6scBdLMe2GzP3A4O1QrVn-e_RojT7Z1aevpywGSwRN_v7HIGJo8hwf-_-t9Bbefpo_iB_7Owy2YC9XkVlEi_XlUKYP65jZg6lNyxxVUSmzdXP07CqEiSITQ82N0a2JGw4pJkhLtrpQE_7mwpsjY8KueHqKg6MPAs1gt65kFbuZzMOdfL8Dhn7GCHSii-hhSKZA_HEBeFwq_c2-kc1CpPU-w38xG_PEycEBQGbiRlNimcnSJd-5PzUPTPjV6GqG6dDNRJME-227zeKZCS2tdqfKBmOUnuq8xjkIYNSIUxbI_6bwcEfC7FRySgt3Y4OKbIEPgcDyDTs8oQBOfnCiGANZcvR_Anf5I-zEuwDFGGfDHMgwzLjXcR85spw9qU2obbOb5zA5k3iSrx_h3nkwJbKHPmu1k3xHkz1S_sSXWd3TjLKAOfxJL9SmGL82BTqkcAhnuYw1kvvATdcSqpwyficlQokHHHQ0EyV0i6L3uABTwEMzsbRrPGCafSKLSLTYwK3PEfIxDaYHUDKSJlSlIKF6wLEWYcUHu0lJMTe2eKd0iKZPu1RnJ_vYdMPAmXhR-ovvIfsDa7aZ7b2TTUBhDnGRCry2nqihzg2ATiZudKqXdEkCvbsSQOACifhYk6fycfNTCf0kDfOZ9c0pUpplh8BwUB9WpxJnFYpkbsJd-ERb1aoSCsVf9ycdj6Dsxfbii0dtYMGEkLo11qnUcUlDGGoJk4K0zPEb097cMDrlZPOUiItrVf4nU09UvWfeTZEPrNG6QY46ppPXUOhUdSnmA_xyyc_KL8raFfpFzYP2MskhgJzHtXdv6K8DJc3JYTo6QUDV17Qp5h3_p8XoZYcOGqhhdKZj5PUTJdUbLg9G9v9xPc1_3xbAQOdEWPLixuc6A7_aVx63gsklgFtypi_2YmjbfBR-9CkA06jneTXAzqkldp7Q5rf_B1sgWshFggbBqEhfL1D7zUvBmxanCiWGTt_BowMtKtmcqfVc0HxcTO2Dn-d1ieNnjrG48yqg-FJa5qGDMtRUIKQ5OR4tD1i9TRqv1e0MxHH7P1HmX2zrs4MwLMInj_dch_e9zqBx1md-Qc9mF7xateu-dW66RuKFZZcP2IqV0UqYbYsqCfsJNrxs_peJTHl1ckjZY-Zz5LAcUihWcaJe-rGokhyKU3nNFCTvlnib3xV4U5dR_wi2eEic4cN-BjQKXvPlyEldJ4r622hoA-_YH6hshAjcJr7_id0l-5mU2Mv2mGYSNd4FSOMoNRJRb5_Dv3kmzqIijVL6qYODnS3MFtc2F2-KJz5ZrF3qT67dol89biHiHaQeA8DKPIqyqkBQ5zbl_GHaXVAAObTpRcQVPQE2a03gUpypB8ZMz_2_dq-DGBeKvM_MZ3V2EhUu7IeXD5fLVJX37TV3atajV91N7AGzmGuSCh26KGq3USbhO0ajQxbDttmjbkGJXZnkSrT7wZ09qx-9iQPCUMqkLLivi0Y9XdvA2hLKwQA3dpHatLGvX4rA938Aw8AplQ-_b2Ao-k28RLWPrDTtnOPyQKpM1lIK0-UOxGdvKThz4ZYbTSQads6RqyU6SoL0ekIKqoqDHoP2YCLeUYn3TZg4yxA9S7M1xWlW70nP3PQlnM8w8_VDT6fyLQkK2z3ZBH206Jza18EMSymgLilp51NLZW_ZHNRcixRB8SkTuenGg5Gs5H70PDHX5YsP2hCqjTuQULPy76besEZqQ9ln-x0Rlqv_6BSbKmuiEm0ymxWrzCGwcNbGQnhchM8a4_IUp5spI7A9OX2DuydexUQEdCsWEBG49fv3xlsa07So_1-MlejZhdTiJr7u2A8WNbYNkgQpfJ1G3ga8k-n_Gd6JLZXwW6wUova_FKssdQekDTX_as3u6Crkvu0BsQ7nhsqdZlrN5wYY1185gOuRSK7RtB-9xUH9lPPK5rz2S5akJEG1wQqLlMnybs3axjAYT-R3Luy9WLqc6gMhlTWEGUbzbGGGM8tQi0WXHcQnOFJP1EV2IYPvJI96aS17kAkRJFunEJOdnOSTojIsjymqmLiHDPtoA9sfelaAB6qAX2KrqAEyrIjFgppQUspxUIkpBiW7tB_xnv49d4dypue-b2c0MTweDQk2ZB3wDG1yfdqFLovGteJMaYtCmSIDPuJokhMKLIssjRPRyOD60xupMl-U1xxAkfhLy4zV2nfPnmIW6oyEAr4Un_lVbqI94DOlFdJd4B64QvK2x_-axOO_PvLPHl8HE4_fw8CHOq0gq32vwhs9VwJqJiFe4ouIqPE_6Dq-X-QM_oflQ17NX4aWbatnL5UD4xbKlJStA1g7QGaIwCgznN5yHsiCsAz3bQLCYyFCmFD9712JYbJKkAfKJoKycIMQ5k5toPsxuFKm7a7i4ChzwYQVgeswJZQD5hG_51MA9qf6FtvzmK0qAKuUy9w_L7ZDce2pswDkcvl-b8qvwJGF7Am91fv_TfdB0m1Sg9MMRLousG1Yyo84in_gxllEipjzQih5ZArbPyctIPhw3Ofs9wVOPnYN-RNtyc_40AWJ5IJIzV6BWZcBV06nQykgbE33i8gtPNFf5Ixpe1dw30nmnwYt2ghykCgc_HIMIzxq5TELnyCb7zXBQH7KrAO5yybqc1aZA_HLq21VMJp7N-nO7ZYPNRHc2DaCeBtpgaYZv9Y5gLfvA5m3n3n5TbiLlh0BARhd2drb8Nj8niCMCvAy6fW4a9woYoTnon41HjQw3uUq3bwsovyb3WwJ69s5UeOvJJC79VgGivQsDWa3i-iunqLcC9y5LKSMzB0_rYc4exH_IU9HQ9xi-FgNYS8eQy6zY9u9WGD_TPj971-izujoJH61reYCqKslZ6xU22PWj0OwmKMk1FOl6b4XBImt_IOzCFO1ZQbz3_vlK1AvvN7Jn4gbQG2NFIrk4mYZWI6KduYCHkI29druk-X5U6k3j6OqSZnBz2uHKExgSoQDbeSqdBrLLxcU64jJIF-hPMdXmbtcfRAgxDYIGgTVWoVTHR-CNhfFEXQELYryH5nrlAseV606X6hpOit0HOWAfw6z9iZq4qhT7yTXTSmW70LiJSZVRMk9Qsas5eiwOG_hYlkKRMaUT43MDHGjd2nFPaaXqU8_6PVM4v0P31olUwBphLkyvmdCKL3DF9Oa8zfMiD4Ab_Dhk3ciYhzzlHqZS3wpnXjimXUM43Nt8ZicePb5SSQ-TtkHN4FKMlzECEqgLEwLs7nkKLJgl10UxgztVkJYeK1vm8TPiSU91GL2ZNReoMLwm73IttzbhewXJnprM57vlg6y6r32g7MwC_aCDjivaXFRUdR-W4vayY9kQHF71ub5YIremxScwBBTSy7enLQBnwkRCa-Moopa0ctSLLNi-65S7SakkavZTs7QJjG6R4dYjrVmAy_e32LgDMTdHvaCNy3M52RsEYSQ9A4u1IVNDoTLZ3zSp5ug-p9nGgcorL2zOlDxCTVLSY9CRRVcV9H0qGsz6putN8YINMZCwWwLbJKLn5zxtlrey7R9Bmu2ULOcenN8r7PTOu5QOlLsYyMgRcCSJLCkggwCYJxOddgOiqH5zx5NepT9pnFPIS9YtpvYmhRtE7B-lRiJYYQbNnwhzztW83gJV7rPTGF6-0dCupfYCcIT9O5M3jIkZvt_dEHGXrlP8QlEziQkiOJH6O2iFQYZOSRNmcGApnHzuNxhE0mS1v3mAcvBVBI04kUzQyaS6RsSmajTIALqIG30BOqlKO-LdQI2hd2wFl7_aTykRfTOS-U1_FjJJlDBgMcyox3xf3GqgdlDDvrHRdE2miHsHhoI8TtJSwCgrf33AM7PBsYe_vSP1u89wxXp2PYKmWSGAs5eZ_2FC_PbeQVi-8OKISWlAy4cZzZvp0xQk5CBVRFU3fAj0byuPM-cwKPlRkiYrs25DhmNzCLwt3kppXFKmc9EEKTjLZqgBsj953OVWlw51-77TewgIyOFq0m9hZiv4apFV6GtOiCjGPyALjhfzAz_YifYfREosaWboDvUcHKeAwXzP2Fs_MCpzhH5fG2LYF4H1_oP0qEpEQYG-huLoQmNkK6zfK-_gSDdaGiDpG1XM-VELcMMPpbqJ_V7Ws0fR-f3V_AsApx9cMWcQKUKz3vn3jdlfQnU6sWzFX5V7Frwjq5kAjg36SvKdU_Jgotaj-P2t0UZL3tzNReTGTMeNRFr6XABSwA1tXq-GZxR7rj7-Hd-reLvwVxs7wifN41xQPjnw3jX5r2Xo9og814WBhU5sem4-5aAxPKd1p8lj1KsPr0s2rqYGICmJgd1Nvlr6420eoJ98OMCg0cML2Gi4EWefHnkZNhaeZWQaAlVahfLF7qeLYiiR9SYOJh2pb_73FDHnzbVj25fPOCLhLdOLK1k3k74erLEzO1qkgt6CJuzVLBdl4wHPoku7IqhRVrmPY5VQKw_IiitdG--rS9urFWw9FgoY1Lj9lpOVH0vAt4sn58FR65zmoyMcRKk89EUJuWHMTOb7aPRKJE8byu5yB6tmff5LiDoW6vOKAdD29dnsev-oI9lbaBLGHtYCTqqt292NOQGXXmmK_RJR6RIMzNpVP-CNpPX2GJUgE4YYEaY1KXlvRrumDmVFDdhCajeUNsB9-xyk1_cy4kXAMSyqkz6PUkU6jVN4Hy7kqcGAiQlfdbo3Z4ualRTEM29ApiG9e9YnrWGSxeizplDjdRX75vYAgRyQfn6J2k6XgfS0qN-4lrDpU-V45L6f0GLdJiYCN6h2m6cAhym4CPzOvP6qFZKjH2FS0uc764-kFi1BOXVIgQJ3eoGVEW0eMrL3aS5NTIGtwjI02N11PHyGe4-ywEGGf8gMzUm-iH1jvqTB6CIgnZbW66kT11fec8faB-VcdVRU0BZPTN7HcRaADqTV3CS40WJh628O8oQa-y_jblTOupLHVwS1H5-zQtMiEdDQFwdOeT3sLtuBNNUbq80zA661licqV0txibrY4Wi1YFDboaTzYcdkCkvDU57TUNoDy02LYIuA4Y9LI4Ks_GPSnzgJ8pBAnqnb4M0h5enkmH4X6M1pcbNpxUeqch8HOf235ECOEg4wBluE-uL7iBJJfRbIbrd2CFzQxMOVDdrle9WjjFn3UC8vnVrC1ujTAZinHJMlyU7npu-Kbn6lQi66T-_zwoT_id_UaUcq0_nU6KuBp-Gt2AGCGuajQL-W_H5-OPh74oDfJkgqBfKBw4njLU1zZ6epjWVF4Y6I8HE77erLvt3QCbSK1Lbqp46pboz0qCEx-I3jbBXYWMZCp_V5OigvGykRFkC7Dipbdxw5lSrtx8LEJEXpyLFfgJ_vmXpJUnEOyCAYJQxFKLFnz8MLw0lzaln_6HRFcTPk90e0Nu5x7SiQ--FXYl5HMZwdV7K7mR6D1UoIsBQUQgAHe0EvWOZvXGlKIy8lfjVRhpf9MZ-scrN-jVouO2o3p82pvrj26OulrSpxc37hnVPy1Q4-nAp74OAxpXD0TfHiiSjXcEWXp5V2STyjMgpjsI-Vx9Ouu81RryrxTkWBSuwBYnGFDvQL9WaA4RbMclQ1U0hFGcKSqNBnm8ocIHLI2KGQ4fdVvvFiRDTcZk-dGZhNB4XenjT_TqdBloiNWs8D7wX9IHEVXWnFOROOPuFhPYtbRWu1E7uuD77p4Q1gLxY88Xxo_ZyupmfI-NerGbhzU6WcO2C4O8EuxA7xFwUm3Tv7tcIdm6XkYj83ONxGetpuIyg1olVauXOT73ULKRH0MX4syhn6NcRdGkNyJcywJ5Q5IcdGRQkMaougS62nbK3tLKxhLhwQYDaX5R9E4Y6wF27h5YVpKOB7inDojJM3qdkb7vZZj8yVUF8nEcTtOKhSOs3BgbzO1JXoimT-Fz1zR5a2cKXtWcKhb-XA5ggJmtC5rbhNAmBYSOX1Bd3OlWODs1Pn9NxeuFj0lUUDAPLbUDc4PTBVeefZqaCjiF8CZw59YJq5_7ZctviHQXH8Gyo4JXtZpHZPw25X7w5CPLQz9PjjftIJov7uIp9iYQXwkR7la8rcS0oLhTcN6NVEM0jUcnzOxAmTnrMM79wf5Cl-w3dABF7dEeUWj6i0HWzVAm3ZJ5-iZHv3muTORQCP-NSOqNan3ZA0cmOYfYYeHkWRCEh4YM2y0wj_tcCiIlXSeknCXglE2NFJTTuNaLlNmqgxcu01YyjFXZ8ALOgC_yyP6-ANoaeHT_0AFtg8zeKmZEOow2DscvtGnmbtCpbE54WjRFsZwILvlH_5M-QyBNImgYXveKqigaovYElWG0xIKEqAsA47vrM_7fhUjQJGI0DQD4DPik_6Mt8RR0TkhQ1NIyMeTBZfLTjYUGx7Lf2Wi3EaBgB1qWQTvnibpG9KVIvg2JNRKyQrPQ4DJ9Vbuq_OmkCmBRjB3AguV4qpOC6d4rpoQZVuEb_p_65HXl2_PoNr-XxOu5FEHcMBr0Eo3uB5Z3XQDg4LVOpETLycx_daWV3VGeXHgbPZgJDT5Fb5jiixKmIiEmiZdclHU0sEvI00nIeXJFAVrnLVNIvPCX-tQbmZ9XP1cNTN95P84mMbPnFiqKcOzpS9GXDoGtdxpVyUZGl0jkem6w0WPlcg6MFEhELLKxP2zXraSQ6h97UpG1RMf8tOtebGEd9GkpVxTVcJooTchmU0rBv9IXuYqWwuSUbjGN_OFmkry84gcVDJnDVyhvOoRa9IzLHRGdD-hbBfmPcKD8bGzF6VVSvZb_msgNvhvBRI7dlSgL-Ci-Fc-E0HrdGN3JNPuS5A9ki2gWT0Kqs5zIa3V_Q5GW1bUzGWlSXRO4Na9wnteDersly_0SyxyTbwqKMAcotjXOKqy2hVyrzkb-btkNmVO6GW7flfG3MoTQOZQhurE-GxXTmWLPXBI7Dw8X2l-2byIZv3J3Qm6IwcPoTutAnPxV831L2VFD3FZjf_wMWBRw36i7zvaGtjHQXbjlhal790dds4iO5os54znsAxwrL9-2T98UzyPHpHf3hB3fEG53bTov51RcMmK5Qo7oip89VX50n1JJ7drbh9lgKnASaCECKv64FCpE62b6Wh9riP6isblgmiPeQDbhi7bSOps5jL-Fk2Op53fgbc77zm5DRf4l1UdVPlYpln_Nn6zZSmDPj3m72O497J0jA-j_OO05ND6fxYk31MHSD-hXnPbK2w-hYopgHS0sFSpv_dn0yy4C_ksxs5GP-aUDrHIOONNjI2SELyheHH2LttEK25qhaXeyvc39djOChprw1VwHaevoxznWH5slzp6K2sR3Ku3Mdy9mGKLcEdihOz8plpb4EoDaIpaqfLxh7R6gukXOwmtUKuVv2o39VHs476iVTG967Mgfq8UASGYyUU36i14d6KEZ6yDVQvAeX9AyDBOsSRO8fW9J7RMIJxj_JdL6ifKcgLtNeH8K4FTxfR--qiHPc3WBfx5nPSQgol1bYrSpZvCNquDZVEUxHqQ2JnSJUijoNZ3A8OZBU_PKNXYWWjt8cHCf8CMaT98E91Y1fZk9N3gkJ6RkcRM5JopLBBWdHjLl82EMgb5DxGydDiZ1G36yq2ufmieWPU12P_HlY1TuRyUautRMnqQ70hS0nftlhd_ZFq2G8n0iTo2Vc_wOJJWKuJzKIWWiLc8QJjxIIUeesmpgBA6QyhidmwEJcym1dQhiPnsodf2H0FVekDw6bWdfjxoENMVaGNVrMAqJ2879nf5dFLMbNLgLwHe6Ro4GFoyHft7tAAI7vJWo_m7UmBEd5dUKZ1cxICiMZEvLVBP3-yhlejA4rla7hMjotOsnj4wnNdpLar3WKZ1mtqsv1xSMkXHc4MXLLYkI0w6JIPepmywKmJdsrrRYow0EjXdWLj7rG3qTUXMXJVQNFZ5_WubVf7gZqUITPjHTepMjhfJbItB2-BMZnp6NHfkJGR6kFvBeGAdFtC7k1M4PXij0jBenMGf9FZuxM-iiLC3hHKBbY2rnayFqhUqsSGjh4yFEkkYMrtZszMQmuvYpI-KUBw6QcfPTYQbp75FIdShauzBykhU2QRfBQtlJs4odtR-KZVZzsCb5uXMYgD0ggBS--o3UHe_IgHQcyHB0jeGMdTStErQlnRRAT2acn_VzWynUUd_ap25z35bZMT4Ncn90pJMrf4kiOLY9ctfS7F7qlyeVIkcl4ldOd3u50WCZsj-GaBnT7-s8_-8LM6uFEVIXDnvyl1w9LwHUpmZxM2FyjP9DN-UZVLUPMRtZlfJ98_36zwpdlHWcGPvsPHlgB5XkQN3xWC2VFaUiN-JwFGpi_oqE8U_hgV6rqBWB1EMEJZG6U81Nk1Uhor3w4oA4PN78ZGMycklvVNDJ4OikRrzXBcNiysaXrCNXmRa6lz84TeblgwcRbWBJ9tLy8UWtiUF8Ju1frak4dr9PUsmlb5bYVzdPxfJYkqgNKZjZyeHKKX7QWz66nHlJq5v8sf-CCoMbmyxD9_VL1CjLkcYAv2jZgQ9S8efNhFjsv9YziQFZMdG_QHbRSjWBCU-Rf-0ehujAmySopb-AjbVOPKQmhVRFLC9t_MUryMbs_nNvg7tiEDjPUoJ9hMvQ28hHG2tDVYxRa7o4Fz2oqrWx-w1Py4AL58TN6nOBG9TDXzruGtKL_R_xeexh3xBezU1EiXfpYQQnNLM5sayYiYhhJCpFW8Ke-qo-OILWyf7w1V39y5GNSB46Tn9bnvOy5lJRJh679eo0kRhq8tm2PgAzeoYAX4thPrp2C2FU0_iByAZ2vPpf79-1KBM9LRMYg7n4wYFn8DVQmNQsQhLp-yYd1ge1CeDMR9GzD1_BAdKS_yvN2yuFvnyAvDOHYpzBn19ZmMJf5IXfVQR1k5e0HVEayYhThvi-57j48wRvg8fKcRptysUWgFs5npsm-dFi8vCLcubYkytKdfNk43llGa0RtWcQqX7wD-nlfBScWewfLlbMY02ksZU1KlFV6sdY3kUZ69tfRhqA0sbKEczR3ErRwEVF9whKGkRRbgcprPnlIFwiFkK73uhMfeKsbqbsZhigwazYgxtp2idspUO4zvy22v-O3RZTi6d3fLLrGW3JJfloBiO6YiQqNIGwHg8l1y0wHdhy2AT-FAJfEtqSdJoxg0PY91P1fSVkOjt-NIMH1mdUDiFxRx8QrmHpXOOHcO4UFvaYxlti9kLML-6ADwRHRZK-b47K-UdqDqrFzBjRDDkqoQwCW3oe5ch3RPCwH29x2gAXcJnZivskqQ80zIQO1NHmsYP-1uNioNwyEdELwyjoxTt2nN5oNELBIPWxdJe1HVmInGscPav6Z8VTtflkdJVPYgM7wx04YSwkqRL7jzxubblo3Y7xuwDZce1_WQ1hQLFWyiQ1Us1-ohNsOvE7cCpfx_AD-lHOHUWD5lG37Uk9httpbXObVshz-Qbi25TGV-tfvOmkOMmrBHZIBkDzgsKjeCuoUj9cfuKLxDtS_CBU6MFBT0-R1SQbOjRHAcLGN_gw5yQi6--6gs9DAgFie0nG5ek4I6kb-nzCgBTfm4JoPnDckVC3WDElTQPGyU9MsxoRqlNYYimAolo-iZMZ6z3gwrXaNTkkZO9JEFe_LqJ0D1n59gmKebistTQaxxxKRW6kIl0UnZbMgCIGCi51OS6IuLaX9KzyJeR8V3zz0woMIrIc8ige7UXGxOEgqVC-pEEXV2BE0yg7Zp8po6ZGcjG8CYG7VCwMA0-lXgIuCSmYeeJr1ju4rIiA54U5X5qNLxzPCPzoeNVeVbMvk_w5QlkwIPzBGmYxhtTmZTeGQycGIkLUYr2bwTKQo3F-5y_3Zwwq_wFOIk-hW_isZJAvPNy5rsA6-UDEkRtX3260KDq7uvxrmsNybKcSmOHvJzotp-ZEhOrohs6Bio3NC30DaDFd3yGgUFet4fHjfYnCBeBOS6fMCZNnNfgXAx66RDgbF7sV_G6v_vTnWLQSFFysSmsRfgZBwMnsPp_cY8izf72te5ZSCwz-PuwJRToaZvFrPv1ej3AEW3u_Efn59A_d6CHS8mYeJZm1dI7sSMyz0bY8U1m"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2407,
              "completion_tokens": 1715,
              "total_tokens": 4122,
              "completion_tokens_details": {
                "reasoning_tokens": 1664
              }
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "cell viability assay",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 2407,
          "output_tokens": 1715,
          "total_tokens": 4122
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 6,
        "input": {
          "diagnosis": "RASopathy",
          "assay": "immunoassay",
          "tumorType": "NFIB"
        },
        "response": {
          "success": true,
          "content": "{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}",
          "model_id": "openrouter/auto",
          "usage": {
            "inputTokens": 2401,
            "outputTokens": 2352,
            "totalTokens": 4753
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584260-cmW13HqQ3AOOcDUKgGJ1",
            "provider": "OpenAI",
            "model": "openai/gpt-5",
            "object": "chat.completion",
            "created": 1763584262,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "completed",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}",
                  "refusal": null,
                  "reasoning": "**Evaluating diagnoses**\n\nI\u2019m focusing on the diagnosis \"RASopathy,\" specifically narrowing it down to \"Noonan Syndrome.\" I think making assumptions without more information can be risky, especially since there are many rasopathies. The only rasopathy in the schema is Noonan Syndrome, but I see \"Juvenile myelomonocytic leukemia\" which may relate to the RAS pathway but isn't a rasopathy. There\u2019s also \"Neurofibromatosis type 1,\" which has some debate around whether it's classified that way. I\u2019m leaning toward \"Unknown.\"**Narrowing diagnoses**\n\nI need to narrow down broad synonyms, but simply swapping \"RASopathy\" with \"Unknown\" isn't the correct approach since it doesn\u2019t target a specific diagnosis. Without proper context, I feel lost. The instructions focus on replacing broad terms with specific ones. The dataset includes tumorType \"NFIB,\" which might relate to NF1, but not necessarily. I see a match with \"Juvenile myelomonocytic leukemia\" in the schema, but I can't assume that\u2019s the diagnosis. Maybe returning an error is a better option?**Deciding on terminology**\n\nThe instruction is clear: I need to return corrected metadata as JSON. So, I\u2019m deciding whether to use \"Unknown\" for the diagnosis to avoid the risk of incorrectly narrowing it down. While \"RASopathy\" is too broad, saying \"Unknown\" doesn\u2019t really narrow it. The goal is to improve specificity based on controlled terminology, yet using \"Unknown\" is sometimes accepted in cases of ambiguity. It\u2019s the safe choice but doesn\u2019t meet the narrowing request. I guess it's appropriate given the lack of context!**Deciding on entries**\n\nI\u2019m considering how to fill out the entries: I\u2019d do diagnosis as \"Unknown,\" keep the assay as \"immunoassay,\" and set tumorType to \"Unknown\" as well. They mentioned a \"Not Applicable\" option, but that feels like it applies only if there\u2019s no tumor present. Since tumorType does exist, I\u2019ll stick with \"Unknown.\" I\u2019m aware \"RASopathy\" generally points to Noonan Syndrome, but I want to avoid assumptions. For tumorType, \"NFIB\" could potentially map to \"Neurofibroma,\" but I'm not entirely confident about that.**Determining final values**\n\nI\u2019m thinking about \"NFIB\" and whether it might actually refer to a \"Nerve Fiber\" or something else entirely. In terms of tumor types, \"Schwannoma\" and \"Neurofibroma\" are common, particularly for NF1 contexts. Mapping \"NFIB\" to an associated tumor like \"Neurofibroma\" feels right, as many specialists use the abbreviation NFib. In the end, I\u2019m concluding that the diagnosis should be set to \"Neurofibromatosis type 1,\" with the tumorType as \"Neurofibroma\" and assay remaining as \"immunoassay.\" Here\u2019s the final JSON structure! \n\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}",
                  "reasoning_details": [
                    {
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.summary",
                      "summary": "**Evaluating diagnoses**\n\nI\u2019m focusing on the diagnosis \"RASopathy,\" specifically narrowing it down to \"Noonan Syndrome.\" I think making assumptions without more information can be risky, especially since there are many rasopathies. The only rasopathy in the schema is Noonan Syndrome, but I see \"Juvenile myelomonocytic leukemia\" which may relate to the RAS pathway but isn't a rasopathy. There\u2019s also \"Neurofibromatosis type 1,\" which has some debate around whether it's classified that way. I\u2019m leaning toward \"Unknown.\"**Narrowing diagnoses**\n\nI need to narrow down broad synonyms, but simply swapping \"RASopathy\" with \"Unknown\" isn't the correct approach since it doesn\u2019t target a specific diagnosis. Without proper context, I feel lost. The instructions focus on replacing broad terms with specific ones. The dataset includes tumorType \"NFIB,\" which might relate to NF1, but not necessarily. I see a match with \"Juvenile myelomonocytic leukemia\" in the schema, but I can't assume that\u2019s the diagnosis. Maybe returning an error is a better option?**Deciding on terminology**\n\nThe instruction is clear: I need to return corrected metadata as JSON. So, I\u2019m deciding whether to use \"Unknown\" for the diagnosis to avoid the risk of incorrectly narrowing it down. While \"RASopathy\" is too broad, saying \"Unknown\" doesn\u2019t really narrow it. The goal is to improve specificity based on controlled terminology, yet using \"Unknown\" is sometimes accepted in cases of ambiguity. It\u2019s the safe choice but doesn\u2019t meet the narrowing request. I guess it's appropriate given the lack of context!**Deciding on entries**\n\nI\u2019m considering how to fill out the entries: I\u2019d do diagnosis as \"Unknown,\" keep the assay as \"immunoassay,\" and set tumorType to \"Unknown\" as well. They mentioned a \"Not Applicable\" option, but that feels like it applies only if there\u2019s no tumor present. Since tumorType does exist, I\u2019ll stick with \"Unknown.\" I\u2019m aware \"RASopathy\" generally points to Noonan Syndrome, but I want to avoid assumptions. For tumorType, \"NFIB\" could potentially map to \"Neurofibroma,\" but I'm not entirely confident about that.**Determining final values**\n\nI\u2019m thinking about \"NFIB\" and whether it might actually refer to a \"Nerve Fiber\" or something else entirely. In terms of tumor types, \"Schwannoma\" and \"Neurofibroma\" are common, particularly for NF1 contexts. Mapping \"NFIB\" to an associated tumor like \"Neurofibroma\" feels right, as many specialists use the abbreviation NFib. In the end, I\u2019m concluding that the diagnosis should be set to \"Neurofibromatosis type 1,\" with the tumorType as \"Neurofibroma\" and assay remaining as \"immunoassay.\" Here\u2019s the final JSON structure! \n\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}"
                    },
                    {
                      "id": "rs_03f2b8cb38470ab101691e2906a3e08190b954b8a2694d00f0",
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2401,
              "completion_tokens": 2352,
              "total_tokens": 4753,
              "completion_tokens_details": {
                "reasoning_tokens": 2304
              }
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "immunocytochemistry",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 2401,
          "output_tokens": 2352,
          "total_tokens": 4753
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 7,
        "input": {
          "diagnosis": "NF",
          "assay": "medical imaging",
          "tumorType": "unknown"
        },
        "response": {
          "success": true,
          "content": "{\n  \"diagnosis\": \"Unknown\",\n  \"assay\": \"conventional MRI\",\n  \"tumorType\": \"Unknown\"\n}",
          "model_id": "openrouter/auto",
          "usage": {
            "inputTokens": 2396,
            "outputTokens": 1443,
            "totalTokens": 3839
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584310-q5XzYlHtMXdtQghgJx6V",
            "provider": "OpenAI",
            "model": "openai/gpt-5",
            "object": "chat.completion",
            "created": 1763584312,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "completed",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "{\n  \"diagnosis\": \"Unknown\",\n  \"assay\": \"conventional MRI\",\n  \"tumorType\": \"Unknown\"\n}",
                  "refusal": null,
                  "reasoning": "**Correcting metadata terms**\n\nI need to refine the metadata by using specific terms from the target schema's enums. The input diagnosis is \"NF,\" which is ambiguous since it stands for Neurofibromatosis, potentially type 1 or type 2. The schema includes specific entries like \"Neurofibromatosis type 1\" and \"NF2-related schwannomatosis.\" Without context, it may be best to set it to \"Unknown.\" However, the instructions emphasize narrowing down broad terms to precise ones, which complicates choosing between \"NF1\" and \"NF2.\"**Narrowing terms thoughtfully**\n\nIn the NF community, \"NF\" usually refers to NF1, NF2, or the schwannomatosis umbrella. Since the schema focuses primarily on schwannomatosis and NF1, I lean towards choosing \"Unknown\" to play it safe. The task is to narrow broad terms, but mapping \"NF\" to \"Neurofibromatosis type 1\" could be incorrect. For \"assay,\" we must specify imaging modalities like structural MRI or conventional MRI, as the general \"medical imaging\" isn\u2019t precise enough. Unfortunately, the schema doesn't include \"Unknown\" as an option for assay, so I need to select something else.**Choosing precise mappings**\n\nFor the term \"medical imaging,\" I think mapping it to \"conventional MRI\" could work as a general reference. However, the instruction emphasizes using exact terms from the Target Schema, which is tricky because there are other options like \"optical tomography\" and \"x-ray computed tomography.\" \"Structural MRI\" seems to be a common choice, but I really need to be precise. By the way, for \"tumorType,\" the enum does include \"Unknown,\" so I can set that accurately as \"Unknown\" with a capital \"U.\" It's all about getting the details right!**Selecting assay terminology**\n\nFor the assay, I think we need to choose a valid term since there\u2019s no \"Unknown\" option. I could go with a general category like \"structural MRI\" or \"conventional MRI.\" Switching \"medical imaging\" to \"conventional MRI\" seems minimal, but I'm questioning if that\u2019s justified. \"X-ray\" is another option as a general term, but without more context, it\u2019s challenging. The goal is to narrow broad terms, so \"structural MRI\" feels right since NF tumors are commonly imaged this way. I just want to ensure everything aligns with the valid enum!**Choosing precise terms for JSON**\n\nI think \"clinical data\" isn't the right fit since it's not imaging-related. I could consider \"x-ray computed tomography\" or \"high frequency ultrasound,\" but without context, I'm leaning towards \"conventional MRI\" since Neurofibromatosis typically uses that. For the diagnosis, \"Neurofibromatosis type 1\" is the most common, although \"NF2-related schwannomatosis\" could also work. With unclear context, setting diagnosis and tumorType to \"Unknown\" seems best. The final JSON will be:  \ndiagnosis: \"Unknown\"  \nassay: \"conventional MRI\"  \ntumorType: \"Unknown\"  \nThis provides clarity while following the instructions!",
                  "reasoning_details": [
                    {
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.summary",
                      "summary": "**Correcting metadata terms**\n\nI need to refine the metadata by using specific terms from the target schema's enums. The input diagnosis is \"NF,\" which is ambiguous since it stands for Neurofibromatosis, potentially type 1 or type 2. The schema includes specific entries like \"Neurofibromatosis type 1\" and \"NF2-related schwannomatosis.\" Without context, it may be best to set it to \"Unknown.\" However, the instructions emphasize narrowing down broad terms to precise ones, which complicates choosing between \"NF1\" and \"NF2.\"**Narrowing terms thoughtfully**\n\nIn the NF community, \"NF\" usually refers to NF1, NF2, or the schwannomatosis umbrella. Since the schema focuses primarily on schwannomatosis and NF1, I lean towards choosing \"Unknown\" to play it safe. The task is to narrow broad terms, but mapping \"NF\" to \"Neurofibromatosis type 1\" could be incorrect. For \"assay,\" we must specify imaging modalities like structural MRI or conventional MRI, as the general \"medical imaging\" isn\u2019t precise enough. Unfortunately, the schema doesn't include \"Unknown\" as an option for assay, so I need to select something else.**Choosing precise mappings**\n\nFor the term \"medical imaging,\" I think mapping it to \"conventional MRI\" could work as a general reference. However, the instruction emphasizes using exact terms from the Target Schema, which is tricky because there are other options like \"optical tomography\" and \"x-ray computed tomography.\" \"Structural MRI\" seems to be a common choice, but I really need to be precise. By the way, for \"tumorType,\" the enum does include \"Unknown,\" so I can set that accurately as \"Unknown\" with a capital \"U.\" It's all about getting the details right!**Selecting assay terminology**\n\nFor the assay, I think we need to choose a valid term since there\u2019s no \"Unknown\" option. I could go with a general category like \"structural MRI\" or \"conventional MRI.\" Switching \"medical imaging\" to \"conventional MRI\" seems minimal, but I'm questioning if that\u2019s justified. \"X-ray\" is another option as a general term, but without more context, it\u2019s challenging. The goal is to narrow broad terms, so \"structural MRI\" feels right since NF tumors are commonly imaged this way. I just want to ensure everything aligns with the valid enum!**Choosing precise terms for JSON**\n\nI think \"clinical data\" isn't the right fit since it's not imaging-related. I could consider \"x-ray computed tomography\" or \"high frequency ultrasound,\" but without context, I'm leaning towards \"conventional MRI\" since Neurofibromatosis typically uses that. For the diagnosis, \"Neurofibromatosis type 1\" is the most common, although \"NF2-related schwannomatosis\" could also work. With unclear context, setting diagnosis and tumorType to \"Unknown\" seems best. The final JSON will be:  \ndiagnosis: \"Unknown\"  \nassay: \"conventional MRI\"  \ntumorType: \"Unknown\"  \nThis provides clarity while following the instructions!"
                    },
                    {
                      "id": "rs_07c2f9d5c98e738901691e2938b5ac81968f52f5e48307cb49",
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2396,
              "completion_tokens": 1443,
              "total_tokens": 3839,
              "completion_tokens_details": {
                "reasoning_tokens": 1408
              }
            }
          }
        },
        "score": 0.6666666666666666,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "conventional MRI",
          "tumorType": "Unknown"
        },
        "token_usage": {
          "input_tokens": 2396,
          "output_tokens": 1443,
          "total_tokens": 3839
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 8,
        "input": {
          "diagnosis": "neurocristopathy",
          "assay": "transcriptomics",
          "tumorType": "neurolemmoma"
        },
        "response": {
          "success": true,
          "content": "{\n  \"diagnosis\": \"Sporadic Schwannoma\",\n  \"assay\": \"transcriptomics\",\n  \"tumorType\": \"Schwannoma\"\n}",
          "model_id": "openrouter/auto",
          "usage": {
            "inputTokens": 2404,
            "outputTokens": 1514,
            "totalTokens": 3918
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584346-8aSMOOin9XtiXwOOEyRX",
            "provider": "OpenAI",
            "model": "openai/gpt-5",
            "object": "chat.completion",
            "created": 1763584348,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "completed",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "{\n  \"diagnosis\": \"Sporadic Schwannoma\",\n  \"assay\": \"transcriptomics\",\n  \"tumorType\": \"Schwannoma\"\n}",
                  "refusal": null,
                  "reasoning": "**Refining diagnosis terms**\n\nI need to replace broad synonyms with more specific equivalents based on the context of tumor type, which is \"neurolemmoma\" or Schwannoma. For example, \"Sporadic Schwannoma\" applies to a single tumor not linked to NF2 or schwannomatosis, but I\u2019m unsure of the association. Then there\u2019s \"Schwannomatosis-NOS\" for unspecified cases. If there\u2019s a pair of bilateral vestibular schwannomas, it could be \"NF2-related schwannomatosis.\" Given the lack of details, it might be best to label the diagnosis as \"Unknown\" to maintain accuracy.**Narrowing diagnosis terms**\n\nI'm tasked with narrowing broad synonyms in the metadata, and \"neurocristopathy\" feels too broad to map to \"Unknown.\" The goal is to replace general terms with more specific ones that fit the context related to Schwannoma. A consistent mapping could be \"Schwannomatosis-NOS,\" but it doesn't feel much narrower than \"Schwannomatosis.\" Since \"Sporadic Schwannoma\" is highly specific, I think I might lean toward that. But I need to clarify whether \"neurolemmoma\" indicates sporadic or syndromic cases, which isn\u2019t clear here. The unspecified NF classification complicates things.**Choosing diagnosis and assay terms**\n\nI need to select specific terms that fit the tumor type, and while \"Schwannomatosis-NOS\" might be too specific, \"Sporadic Schwannoma\" feels like a safe default for a single case. The instructions indicate that we should match exact values from the schema without inferring synonyms, so I\u2019ll go with that. For the assay, \"transcriptomics\" is fine, but they may prefer \"RNA-seq.\" Since we don\u2019t have info about sequencing, I'll stick with \"transcriptomics.\" The mapping for tumor type to \"Schwannoma\" is straightforward, so I\u2019ll propose the final JSON structure with those terms.**Finalizing diagnosis term**\n\nI noticed that some systems might typically prefer \"Vestibular Schwannoma,\" but I\u2019m deciding against that for this context. It seems more fitting to stick with the previously chosen terms based on the specific requirements outlined. I\u2019ll finalize the selections now without the \"Vestibular\" designation, ensuring accuracy and consistency with the diagnosis. It\u2019s essential to adhere to the specific context provided for the task, so I\u2019m confident in keeping things straightforward.",
                  "reasoning_details": [
                    {
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.summary",
                      "summary": "**Refining diagnosis terms**\n\nI need to replace broad synonyms with more specific equivalents based on the context of tumor type, which is \"neurolemmoma\" or Schwannoma. For example, \"Sporadic Schwannoma\" applies to a single tumor not linked to NF2 or schwannomatosis, but I\u2019m unsure of the association. Then there\u2019s \"Schwannomatosis-NOS\" for unspecified cases. If there\u2019s a pair of bilateral vestibular schwannomas, it could be \"NF2-related schwannomatosis.\" Given the lack of details, it might be best to label the diagnosis as \"Unknown\" to maintain accuracy.**Narrowing diagnosis terms**\n\nI'm tasked with narrowing broad synonyms in the metadata, and \"neurocristopathy\" feels too broad to map to \"Unknown.\" The goal is to replace general terms with more specific ones that fit the context related to Schwannoma. A consistent mapping could be \"Schwannomatosis-NOS,\" but it doesn't feel much narrower than \"Schwannomatosis.\" Since \"Sporadic Schwannoma\" is highly specific, I think I might lean toward that. But I need to clarify whether \"neurolemmoma\" indicates sporadic or syndromic cases, which isn\u2019t clear here. The unspecified NF classification complicates things.**Choosing diagnosis and assay terms**\n\nI need to select specific terms that fit the tumor type, and while \"Schwannomatosis-NOS\" might be too specific, \"Sporadic Schwannoma\" feels like a safe default for a single case. The instructions indicate that we should match exact values from the schema without inferring synonyms, so I\u2019ll go with that. For the assay, \"transcriptomics\" is fine, but they may prefer \"RNA-seq.\" Since we don\u2019t have info about sequencing, I'll stick with \"transcriptomics.\" The mapping for tumor type to \"Schwannoma\" is straightforward, so I\u2019ll propose the final JSON structure with those terms.**Finalizing diagnosis term**\n\nI noticed that some systems might typically prefer \"Vestibular Schwannoma,\" but I\u2019m deciding against that for this context. It seems more fitting to stick with the previously chosen terms based on the specific requirements outlined. I\u2019ll finalize the selections now without the \"Vestibular\" designation, ensuring accuracy and consistency with the diagnosis. It\u2019s essential to adhere to the specific context provided for the task, so I\u2019m confident in keeping things straightforward."
                    },
                    {
                      "id": "rs_06c53088e28e0af001691e295d2bc4819588924e01c0bc002d",
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2404,
              "completion_tokens": 1514,
              "total_tokens": 3918,
              "completion_tokens_details": {
                "reasoning_tokens": 1472
              }
            }
          }
        },
        "score": 0.0,
        "ground_truth": {
          "diagnosis": "NF2-related schwannomatosis",
          "assay": "RNA-seq",
          "tumorType": "schwannoma"
        },
        "token_usage": {
          "input_tokens": 2404,
          "output_tokens": 1514,
          "total_tokens": 3918
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 9,
        "input": {
          "diagnosis": "phakomatosis",
          "assay": "viability assay",
          "tumorType": "tumor of cranial and spinal nerves"
        },
        "response": {
          "success": true,
          "content": "{\n  \"diagnosis\": \"NF2-related schwannomatosis\",\n  \"assay\": \"cell viability assay\",\n  \"tumorType\": \"Schwannoma\"\n}",
          "model_id": "openrouter/auto",
          "usage": {
            "inputTokens": 2407,
            "outputTokens": 1580,
            "totalTokens": 3987
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584385-GWphb9FnkXwykljNpLC7",
            "provider": "OpenAI",
            "model": "openai/gpt-5",
            "object": "chat.completion",
            "created": 1763584387,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "completed",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "{\n  \"diagnosis\": \"NF2-related schwannomatosis\",\n  \"assay\": \"cell viability assay\",\n  \"tumorType\": \"Schwannoma\"\n}",
                  "refusal": null,
                  "reasoning": "**Mapping diagnostic terms**\n\nI need to match broad terms to controlled schema enums. For instance, the term \"phakomatosis\" is too broad as it encompasses various neurocutaneous syndromes. In the context of my dataset, which includes NF1, NF2, and schwannomatosis, \"phakomatosis\" doesn't specify which condition fits best. I should aim for a more specific term aligned with this schema. While I could select \"Unknown,\" it wouldn\u2019t narrow down effectively unless the context is clearer. It's essential to adhere to the directive to replace broad terms with specific ones.**Refining tumor classifications**\n\nFor the TumorType labeled as \"tumor of cranial and spinal nerves,\" it feels too broad. It could specifically refer to \"Schwannoma\" or \"Neurofibroma,\" but not \"Meningioma\" since that's related to the meninges. Typically, cranial and spinal nerve tumors include schwannomas and neurofibromas. If unspecified, I'd likely map it to \"Schwannoma\" because vestibular schwannomas are common. However, \"Neurofibroma\" could apply too. For \"viability assay,\" I should narrow it down to \"cell viability assay\" since that fits best with the schema.**Analyzing tumor classification**\n\nI'm considering that the tumor type could be \"NF2-related schwannomatosis\" according to the new nomenclature, as the schema includes that term. If we have a tumor related to cranial and spinal nerves, it suggests NF2 rather than broad \"phakomatosis.\" While \"phakomatosis\" encompasses conditions like NF1, NF2, TSC, and others, narrowing it down to \"NF2-related schwannomatosis\" feels precise but is it too assumptive without more context? Given that cranial nerve tumors more often relate to NF2, I'd probably lean toward \"Schwannoma\" as the diagnosis.**Determining tumor classification**\n\nIf I conclude that the TumorType is \"Schwannoma,\" I might consider the diagnosis as either \"Schwannomatosis-NOS\" or \"NF2-related,\" but I\u2019m not entirely sure. It's also possible that the diagnosis could be sporadic vestibular schwannoma. Since the initial diagnosis points to phakomatosis, which includes genetic syndromes like NF2, I think choosing \"NF2-related schwannomatosis\" aligns with modern naming conventions. \n\nI need to ensure my output is in JSON format and matches the required fields:  \n\nFor the assay, I\u2019ll go with \"cell viability assay\". For tumorType, I\u2019ll narrow down to \"Schwannoma\" since it\u2019s more prevalent in cranial nerves. Finally, for diagnosis, it could be \"NF2-related schwannomatosis,\" \"Schwannomatosis,\" or possibly \"Vestibular Schwannoma,\" although we don\u2019t have that specificity yet.**Finalizing tumor mapping**\n\nI'm looking at the terms available: \"Schwannomatosis,\" \"Schwannomatosis-NOS,\" and \"Schwannomatosis-NEC.\" For this context, \"NF2-related schwannomatosis\" feels like a narrower choice, especially for phakomatosis, but maybe too specific if there's no explicit evidence of NF2. The presence of cranial and spinal nerve tumors certainly indicates NF2 might be involved, so I think \"NF2-related schwannomatosis\" is appropriate.\n\nTo finalize, my choices are:\n- diagnosis: \"NF2-related schwannomatosis\"\n- assay: \"cell viability assay\"\n- tumorType: \"Schwannoma\"\n\nI\u2019ll check the enums\u2014everything matches perfectly. Now, I'll return the corrected metadata in JSON format, ensuring the variable names match the input. Everything looks good for the final output!",
                  "reasoning_details": [
                    {
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.summary",
                      "summary": "**Mapping diagnostic terms**\n\nI need to match broad terms to controlled schema enums. For instance, the term \"phakomatosis\" is too broad as it encompasses various neurocutaneous syndromes. In the context of my dataset, which includes NF1, NF2, and schwannomatosis, \"phakomatosis\" doesn't specify which condition fits best. I should aim for a more specific term aligned with this schema. While I could select \"Unknown,\" it wouldn\u2019t narrow down effectively unless the context is clearer. It's essential to adhere to the directive to replace broad terms with specific ones.**Refining tumor classifications**\n\nFor the TumorType labeled as \"tumor of cranial and spinal nerves,\" it feels too broad. It could specifically refer to \"Schwannoma\" or \"Neurofibroma,\" but not \"Meningioma\" since that's related to the meninges. Typically, cranial and spinal nerve tumors include schwannomas and neurofibromas. If unspecified, I'd likely map it to \"Schwannoma\" because vestibular schwannomas are common. However, \"Neurofibroma\" could apply too. For \"viability assay,\" I should narrow it down to \"cell viability assay\" since that fits best with the schema.**Analyzing tumor classification**\n\nI'm considering that the tumor type could be \"NF2-related schwannomatosis\" according to the new nomenclature, as the schema includes that term. If we have a tumor related to cranial and spinal nerves, it suggests NF2 rather than broad \"phakomatosis.\" While \"phakomatosis\" encompasses conditions like NF1, NF2, TSC, and others, narrowing it down to \"NF2-related schwannomatosis\" feels precise but is it too assumptive without more context? Given that cranial nerve tumors more often relate to NF2, I'd probably lean toward \"Schwannoma\" as the diagnosis.**Determining tumor classification**\n\nIf I conclude that the TumorType is \"Schwannoma,\" I might consider the diagnosis as either \"Schwannomatosis-NOS\" or \"NF2-related,\" but I\u2019m not entirely sure. It's also possible that the diagnosis could be sporadic vestibular schwannoma. Since the initial diagnosis points to phakomatosis, which includes genetic syndromes like NF2, I think choosing \"NF2-related schwannomatosis\" aligns with modern naming conventions. \n\nI need to ensure my output is in JSON format and matches the required fields:  \n\nFor the assay, I\u2019ll go with \"cell viability assay\". For tumorType, I\u2019ll narrow down to \"Schwannoma\" since it\u2019s more prevalent in cranial nerves. Finally, for diagnosis, it could be \"NF2-related schwannomatosis,\" \"Schwannomatosis,\" or possibly \"Vestibular Schwannoma,\" although we don\u2019t have that specificity yet.**Finalizing tumor mapping**\n\nI'm looking at the terms available: \"Schwannomatosis,\" \"Schwannomatosis-NOS,\" and \"Schwannomatosis-NEC.\" For this context, \"NF2-related schwannomatosis\" feels like a narrower choice, especially for phakomatosis, but maybe too specific if there's no explicit evidence of NF2. The presence of cranial and spinal nerve tumors certainly indicates NF2 might be involved, so I think \"NF2-related schwannomatosis\" is appropriate.\n\nTo finalize, my choices are:\n- diagnosis: \"NF2-related schwannomatosis\"\n- assay: \"cell viability assay\"\n- tumorType: \"Schwannoma\"\n\nI\u2019ll check the enums\u2014everything matches perfectly. Now, I'll return the corrected metadata in JSON format, ensuring the variable names match the input. Everything looks good for the final output!"
                    },
                    {
                      "id": "rs_0ed15a23bcc05a4001691e2983d8748194863f7def03e7f404",
                      "format": "openai-responses-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2407,
              "completion_tokens": 1580,
              "total_tokens": 3987,
              "completion_tokens_details": {
                "reasoning_tokens": 1536
              }
            }
          }
        },
        "score": 0.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "3D microtissue viability",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 2407,
          "output_tokens": 1580,
          "total_tokens": 3987
        },
        "tool_calls": [],
        "tool_execution_history": []
      }
    ],
    "metrics": {
      "total_samples": 10,
      "successful_runs": 10,
      "failed_runs": 0,
      "success_rate": 1.0,
      "average_score": 0.3333333333333333,
      "min_score": 0.0,
      "max_score": 0.6666666666666666,
      "num_scored": 10
    },
    "duration_seconds": 372.6594033241272,
    "token_usage": {
      "input_tokens": 24030,
      "output_tokens": 14514,
      "total_tokens": 38544
    }
  }
}